var title_f11_9_11408="Miliary TB pulmonary lesions";
var content_f11_9_11408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extensive miliary pulmonary lesions in disseminated TB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive miliary pulmonary lesions in a young child with disseminated tuberculosis. The child presented in a shock-like state with extreme respiratory distress, weight loss and fever. After appropriate treatment, the child had a full recovery and a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey R Starke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11408=[""].join("\n");
var outline_f11_9_11408=null;
var title_f11_9_11409="TB chest radiograph 1";
var content_f11_9_11409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Chest radiographs of tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiographs (posteroanterior and lateral views) demonstrating cavitary reactivation of latent tuberculosis infection in the posterior apical segment of the right upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Crapo JD, Glassroth J, Karlinsky JB, King TE. Baum's Textbook of Pulmonary Diseases, 7th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11409=[""].join("\n");
var outline_f11_9_11409=null;
var title_f11_9_11410="Cystic hygroma CXR II";
var content_f11_9_11410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma involving right axilla and mediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph demonstrates a large right-sided mediastinal mass displacing the trachea to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11410=[""].join("\n");
var outline_f11_9_11410=null;
var title_f11_9_11411="Morphologic variants HCM";
var content_f11_9_11411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Morphologic variants of hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypertrophic cardiomyopathy (HCM) typically presents with asymmetric or localized areas of left ventricular hypertrophy which are diagrammed in B to E. A: Normal LV wall thickness; B: Asymmetrical septal hypertrophy (ASH); C: Sigmoid septum which is more common in the elderly; D Midcavity hypertrophy associated with midcavity obstruction; E: Predominantly free wall hypertrophy, an unusual pattern in HCM ; F: LV wall thinning (associated with low left ventricular ejection fraction) and biatrial enlargement; G: Predominantly apical LV hypertrophy; H: Severe concentric hypertrophy with cavity obliteration; I: Biventricular hypertrophy; J: Mild to moderate symmetric hypertrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11411=[""].join("\n");
var outline_f11_9_11411=null;
var title_f11_9_11412="Typical facial features in a patient with Fragile X syndrome";
var content_f11_9_11412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical facial features in a patient with Fragile X syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four-year-old boy with Fragile X syndrome displays some of the typical facial features of the disorder including:",
"    <br>",
"     <ul>",
"      <li>",
"       A long and narrow face with prominent forehead and chin (prognathism)",
"      </li>",
"      <li>",
"       Large ears",
"      </li>",
"      <li>",
"       Midface hypoplasia with sunken eyes",
"      </li>",
"      <li>",
"       Strabismus",
"      </li>",
"     </ul>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11412=[""].join("\n");
var outline_f11_9_11412=null;
var title_f11_9_11413="Protamine sulfate: Drug information";
var content_f11_9_11413=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Protamine sulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"    see \"Protamine sulfate: Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/62/25571?source=see_link\">",
"    see \"Protamine sulfate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7255805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heparin neutralization:",
"     </b>",
"     I.V.: Protamine dosage is determined by the dosage of heparin; 1 mg of protamine neutralizes ~100 units of heparin; maximum dose: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When heparin is given as a continuous I.V. infusion, only heparin given in the preceding several hours should be considered when administering protamine. For example, a patient receiving heparin at 1250 units/hour will require ~30 mg of protamine for reversal of heparin given in the last 2-2.5 hours (Garcia, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heparin overdosage, following intravenous administration:",
"     </b>",
"     I.V.: Since blood heparin concentrations decrease rapidly",
"     <b>",
"      after",
"     </b>",
"     administration, adjust the protamine dosage depending upon the duration of time since heparin administration as follows: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"111\">",
"     </col>",
"     <col align=\"center\" width=\"248\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Time Elapsed",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Dose of Protamine (mg) to Neutralize 100 units of Heparin",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Immediate",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1-1.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         30-60 min",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-0.75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;2 h",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.25-0.375",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heparin overdosage, following SubQ injection:",
"     </b>",
"     I.V.: 1-1.5 mg protamine per 100 units heparin; this may be done by a portion of the dose (eg, 25-50 mg) given slowly I.V. followed by the remaining portion as a continuous infusion over 8-16 hours (the expected absorption time of the SubQ heparin dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      LMWH overdose (unlabeled use):",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Anti-Xa activity is never completely neutralized (maximum: ~60% to 75%). Excessive protamine doses may worsen bleeding potential.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enoxaparin (Lovenox&reg; prescribing information, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Enoxaparin administered in &le;8 hours:",
"     </i>",
"     Dose of protamine should equal the dose of enoxaparin administered. Therefore, 1 mg of protamine sulfate neutralizes 1 mg of enoxaparin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Enoxaparin administered in &gt; 8 hours or if it has been determined that a second dose of protamine is required (eg, if aPTT measured 2-4 hours after the first dose remains prolonged or if bleeding continues):",
"     </i>",
"     0.5 mg of protamine sulfate for every 1 mg of enoxaparin administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dalteparin or tinzaparin (Fragmin &reg; prescribing information, 2010; Innohep&reg; prescribing information, 2010): 1 mg protamine for each 100 anti-Xa units of dalteparin or tinzaparin; if PTT prolonged 2-4 hours after first dose (or if bleeding continues), consider additional dose of 0.5 mg for each 100 anti-Xa units of dalteparin or tinzaparin.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"      see \"Protamine sulfate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 10 mg/mL (5 mL, 25 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F215128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. use only;",
"     <b>",
"      incompatible",
"     </b>",
"     with cephalosporins and penicillins; administer slow IVP (50 mg over 10 minutes); rapid I.V. infusion causes hypotension; inject without further dilution over 1-3 minutes; maximum of 50 mg in any 10-minute period",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F215173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Iohexol 64.7%, iopamidol 61%, iothalamate meglumine 60%.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide, ioxaglate meglumine 39.3%, ioxaglate sodium 19.6%.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of heparin overdosage; neutralize heparin during surgery or dialysis procedures",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F215164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of low molecular weight heparin (LMWH) overdose",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Protamine may be confused with ProAmatine, Protonix&reg;, Protopam&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Sudden fall in blood pressure, bradycardia, flushing, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Lassitude",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to protamine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin rebound: Heparin rebound associated with anticoagulation and bleeding has been reported to occur occasionally; symptoms typically occur 8-9 hours after protamine administration, but may occur as long as 18 hours later.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: May cause hypersensitivity reaction in patients (have epinephrine 1:1000 and resuscitation equipment available).",
"     <b>",
"      [U.S. Boxed Warning]: Hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, pulmonary vasoconstriction, and pulmonary hypertension may occur. Risk factors for such events include use of high doses or overdose, repeated doses, previous protamine administration (including protamine-containing drugs), fish allergy, vasectomy, severe left ventricular dysfunction, and abnormal preoperative pulmonary hemodynamics.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Too rapid administration can cause severe hypotensive and anaphylactoid-like reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac surgery patients: May be ineffective in some patients following cardiac surgery despite adequate doses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2004). Protamine sulfate may be used during delivery to reduce the risk of bleeding following maternal use of heparin or low molecular weight heparin (LMWH) (Bates,  2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F215145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Protamine Sulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (5 mL): $7.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F215123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coagulation test, aPTT or ACT, cardiac monitor and blood pressure monitor required during administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Denpru (AR);",
"     </li>",
"     <li>",
"      Prosulf (GB);",
"     </li>",
"     <li>",
"      Protamina (ES);",
"     </li>",
"     <li>",
"      Protamina solfato (IT);",
"     </li>",
"     <li>",
"      Protamine Choay (FR);",
"     </li>",
"     <li>",
"      Protamine Sulfate Injection (AU);",
"     </li>",
"     <li>",
"      Protamine Sulphate (GB);",
"     </li>",
"     <li>",
"      Protamine Sulphate Injection BP (AU);",
"     </li>",
"     <li>",
"      Protamini Sulfas (FI);",
"     </li>",
"     <li>",
"      Protaminsulfat (NO);",
"     </li>",
"     <li>",
"      Protaminsulfat Novo (AT);",
"     </li>",
"     <li>",
"      Protaminsulfat &rdquo;Leo&rdquo; (DE, DK);",
"     </li>",
"     <li>",
"      Protaminum Sulfuricum (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combines with strongly acidic heparin to form a stable complex (salt) neutralizing the anticoagulant activity of both drugs",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: I.V.: Heparin neutralization: ~5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~7 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aren C, &ldquo;Heparin and Protamine Therapy,&rdquo;",
"      <i>",
"       Semin Thorac Cardiovasc Surg",
"      </i>",
"      , 1990, 2(4):364-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/2091796/pubmed\" id=\"2091796\" target=\"_blank\">",
"        2091796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e691-736.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/22315276/pubmed\" id=\"22315276\" target=\"_blank\">",
"        22315276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaherty ML, &ldquo;Anticoagulant-Associated Intracerebral Hemorrhage,&rdquo;",
"      <i>",
"       Semin Neuro",
"      </i>",
"      , 2010, 30(5):565-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/21207349/pubmed\" id=\"21207349\" target=\"_blank\">",
"        21207349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fragmin&reg; prescribing information, Pfizer Inc., New York, NY. October 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):24-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/22315264/pubmed\" id=\"22315264\" target=\"_blank\">",
"        22315264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horrow JC, &ldquo;Protamine: A Review of Its Toxicity,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1985, 64(3):348-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/3883848/pubmed\" id=\"3883848\" target=\"_blank\">",
"        3883848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Innohep&reg; prescribing information, LEO Pharma Inc., Parsippany, NJ. May 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaques LB, &ldquo;Protamine - Antagonist to Heparin,&rdquo;",
"      <i>",
"       Can Med Assoc J",
"      </i>",
"      , 1973, 108(10):1291-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/4122234/pubmed\" id=\"4122234\" target=\"_blank\">",
"        4122234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kondo NI, Maddi R, Ewenstein BM, et al, &ldquo;Anticoagulation and Hemostasis in Cardiac Surgical Patients,&rdquo;",
"      <i>",
"       J Card Surg",
"      </i>",
"      , 1994, 9(4):443-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/7949674/pubmed\" id=\"7949674\" target=\"_blank\">",
"        7949674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindblad B, &ldquo;Protamine Sulfate: A Review of Its Effects - Hypersensitivity and Toxicity,&rdquo;",
"      <i>",
"       Eur J Vasc Surg",
"      </i>",
"      , 1989, 3(3):195-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/2663545/pubmed\" id=\"2663545\" target=\"_blank\">",
"        2663545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lovenox &reg; prescribing information, Sanofi-Aventis U.S. LLC, Bridgewater, NJ. April 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Makris M, Hough RE, and Kitchen S, et al, &ldquo;Poor Reversal of Low Molecular Weight Heparin by Protamine,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2000, 108(4): 884-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/10691848/pubmed\" id=\"10691848\" target=\"_blank\">",
"        10691848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wakefield TW and Stanley JC, &ldquo;Intraoperative Heparin Anticoagulation and Its Reversal,&rdquo;",
"      <i>",
"       Semin Vasc Surg",
"      </i>",
"      , 1996, 9(4):296-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/9/11413/abstract-text/8958606/pubmed\" id=\"8958606\" target=\"_blank\">",
"        8958606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9831 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11413=[""].join("\n");
var outline_f11_9_11413=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7255805\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215167\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215140\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215156\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215141\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215125\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215111\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215128\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215173\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215126\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215164\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215175\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215165\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215131\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215115\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299956\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222615\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215121\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801118\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215145\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323746\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215123\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038788\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215114\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215130\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9831\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9831|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/62/25571?source=related_link\">",
"      Protamine sulfate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=related_link\">",
"      Protamine sulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_9_11414="Fetal extraction at cesarean delivery";
var content_f11_9_11414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fetal extraction at cesarean delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11414/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11414/contributors\">",
"     James Greenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11414/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11414/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11414/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11414/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/9/11414/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any surgical procedure, anticipating potential difficulties during cesarean delivery and preventing these difficulties or having a plan for management is always the best practice. Although much has been written about techniques for managing difficult vaginal deliveries, there is a paucity of literature to assist obstetricians with a difficult cesarean delivery. The only information available is from case reports, small case series, and expert opinion.",
"   </p>",
"   <p>",
"    Difficult fetal extraction occurs in 1 to 2 percent of cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/1\">",
"     1",
"    </a>",
"    ]. Causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impacted fetal head",
"     </li>",
"     <li>",
"      Floating fetal head",
"     </li>",
"     <li>",
"      Extremely low birth weight infant",
"     </li>",
"     <li>",
"      Transverse fetal lie (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22662?source=see_link\">",
"       \"Management of the fetus in transverse lie\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Low anterior placenta (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42952?source=see_link&amp;anchor=H24#H24\">",
"       \"Management of placenta previa\", section on 'Cesarean procedure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bandl's ring (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link&amp;anchor=H2329566#H2329566\">",
"       \"Cesarean delivery: Technique\", section on 'Bandl's ring'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the most important initial steps in managing a difficult cesarean delivery is anticipation. In most cases, understanding what difficulties may be encountered should allow mobilization of the proper resources, both personnel and equipment, prior to initiation of the procedure.",
"   </p>",
"   <p>",
"    At a minimum, obstetricians should always be willing to extend the skin, abdominal wall (",
"    <a class=\"graphic graphic_figure graphicRef53422 \" href=\"UTD.htm?31/13/31960\">",
"     figure 1",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uterine incision when needed to accomplish atraumatic delivery of the infant.",
"   </p>",
"   <p>",
"    This topic will focus on additional methods for managing some of the most commonly encountered difficult cesarean delivery situations, such as the impacted fetal head, floating head, and extremely",
"    <span class=\"nowrap\">",
"     premature/low",
"    </span>",
"    birth weight fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UNCOMPLICATED DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hysterotomy incision is made and the fetal membranes are ruptured. If labor has been prolonged and the head is deep in the pelvis, the lower uterine segment may be very thin and retracted superiorly. In these cases, it is important to avoid making the incision too inferiorly as it may transect the cervix or vagina.",
"   </p>",
"   <p>",
"    For fetuses in cephalic presentation, the obstetrician usually inserts",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    dominant hand through the hysterotomy incision and around the top of the fetal head. Standing on a stool may be helpful. Using the fingers and palm, the head is gently elevated and flexed to bring the occiput into the open hysterotomy, and then it is guided through the incision, aided by modest transabdominal fundal pressure from the other hand or an assistant, as needed (",
"    <a class=\"graphic graphic_figure graphicRef80515 \" href=\"UTD.htm?31/31/32242\">",
"     figure 2",
"    </a>",
"    ). The shoulders are then delivered using gentle traction to guide one, and then the other, through the hysterotomy, using fundal pressure as needed; the rest of the body should follow easily. The key to this procedure is getting the fingers around the curvature of the head for leverage and lifting without overly flexing the wrist and using the lower uterine segment as a fulcrum, which, if done improperly, can lead to extensions of the hysterotomy incision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMPACTED HEAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deeply engaged fetal heads that are difficult to deliver complicate about 1.5 percent of cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/1\">",
"     1",
"    </a>",
"    ]. These cases often follow a prolonged second stage and failed attempts at operative vaginal delivery. The impacted head and its management place the infant at increased risk of intracranial hemorrhage, skull fractures, neck fractures, and asphyxial injuries, while simultaneously increasing the risk of maternal complications, such as severe uterine lacerations and hysterotomy extension, damage to the uterine vessels, cervical laceration, infection, and injury to the lower urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/2\">",
"     2",
"    </a>",
"    ]. It is difficult to distinguish the adverse effects attributable to events preceding the difficult disengagement from the adverse effects attributable to disengagement maneuvers.",
"   </p>",
"   <p>",
"    The best methods to disimpact the deeply engaged fetal head include abdominovaginal delivery, use of a head elevator, the reverse breech extraction technique, and Patwardhan&rsquo;s shoulders first technique. For all methods, adequate uterine relaxation and adequate uterine and abdominal wall incisions are important. Uterine relaxation can be achieved quickly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , which can be administered by the anesthesiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abdominovaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominovaginal delivery refers to a procedure whereby a hand inserted vaginally is used to facilitate abdominal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/3\">",
"     3",
"    </a>",
"    ]. The mother's legs are abducted into the \"Whitmore\" or \"frog\" position on the operating room table. An assistant uses",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    gloved cupped hand to gently push the impacted fetal head from the vagina back into the uterus. The assistant should apply three or four fingers spread out over as large an area as possible to prevent excessive focal pressure on the fetal skull. &nbsp;This is less traumatic than applying point pressure on the skull with two fingers side by side [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/4\">",
"     4",
"    </a>",
"    ]. The operating obstetrician also assists by providing steady upward pressure on the fetal shoulders through the incision and by attempting to flex the fetal head or at least prevent further deflexion.",
"   </p>",
"   <p>",
"    While the use of an assistant's hand from below is the preferred method to accomplish this maneuver, the operating obstetrician can also perform this task, but should change gloves before continuing the abdominal procedure. One hand in the uterus is used to prevent further deflexion and the other hand is placed in the vagina to push the head up [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While this technique is generally successful in dislodging the impacted fetal head so abdominal delivery can be completed in the usual manner, it also increases the risk of extended uterine lacerations, with injury to the maternal urinary tract, uterine vasculature, and cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Additionally, it has been associated with serious fetal morbidity, including neonatal skull fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/8\">",
"     8",
"    </a>",
"    ], so care must be taken to avoid excessive pressure on the fetal skull when pushing up from below.",
"   </p>",
"   <p>",
"    If abdominovaginal delivery is anticipated, both the abdomen and perineum should be prepped preoperatively. Even so, the risk of postpartum maternal infection is increased due to contamination of the operative field by vaginal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fetal head elevators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal head elevators or obstetrical spoons are available in several variations, including the Coyne spoon (",
"    <a class=\"graphic graphic_figure graphicRef63801 \" href=\"UTD.htm?23/10/23725\">",
"     figure 3",
"    </a>",
"    ), the Sellheim spoon (",
"    <a class=\"graphic graphic_figure graphicRef79379 \" href=\"UTD.htm?2/38/2670\">",
"     figure 4",
"    </a>",
"    ), and the Murless head extractor (",
"    <a class=\"graphic graphic_figure graphicRef54227 \" href=\"UTD.htm?10/45/10975\">",
"     figure 5",
"    </a>",
"    ). All three instruments essentially function as obstetrical \"shoe horns.\" They take up less space than the obstetrician's hand, thus they are easier to get around a tightly impacted head.",
"   </p>",
"   <p>",
"    With each instrument, the smooth, rounded edge is carefully slipped into the uterus, between the lower uterine segment and the fetal head. Using the handle, the instrument and fetal head are then carefully elevated out of the pelvis and the delivery is completed in the usual manner. With this technique, care must be taken to lift the handle vertically or cephalad (relative to the mother), rather than forcing it caudad (like a shoe horn), to avoid injury to the maternal bladder and to minimize extension of the incision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Reverse breech extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse breech extraction was described by Fong and Arulkumaran in Singapore in 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/9\">",
"     9",
"    </a>",
"    ], but has received little attention in the United States. The operator's hand is inserted into the uterus towards the fundus to grasp the fetal feet, which are then pulled to perform a footling breech extraction (",
"    <a class=\"graphic graphic_figure graphicRef74863 \" href=\"UTD.htm?28/32/29186\">",
"     figure 6",
"    </a>",
"    ). When grasping and pulling the feet, care must be taken to apply traction only parallel to the axis of the legs to avoid fracturing the fetal tibia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibula. Once the feet are through the hysterotomy incision, the delivery is accomplished as a typical breech delivery, with care taken to avoid hyperextension of the fetal neck. If the uterine incision is too small, extension of the uterine incision is likely. Some authors have recommended using a low vertical hysterotomy incision if difficult fetal extraction is expected, or extending a transverse incision into a &lsquo;T&rsquo; or &lsquo;J&rsquo; shaped incision [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with the traditional abdominopelvic delivery technique, the reverse breech extraction technique has been reported to reduce uterine",
"    <span class=\"nowrap\">",
"     lacerations/extension",
"    </span>",
"    of the incision, as well as maternal infectious morbidity and blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/1,7,11,12\">",
"     1,7,11,12",
"    </a>",
"    ]. In the only randomized trial comparing the &ldquo;pull&rdquo; versus &ldquo;push&rdquo; techniques, patients in the pull group had significantly lower rates of maternal morbidity (shorter operating time [56 versus 89 minutes] minutes, less blood loss [898 versus 1257 mL], fewer extensions of the uterine incision [11 versus 30 percent of cases], less endometritis [35 versus 57 percent], shorter hospital stay [11 versus 14 days]) and less fetal morbidity than patients in the push group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/7\">",
"     7",
"    </a>",
"    ]. These results may not be generalizable, as this was a small (108 patient) study of women with prolonged obstructed labor who presented to the emergency room of the obstetric units of teaching hospitals in Nigeria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18614340\">",
"    <span class=\"h2\">",
"     Patwardhan shoulders first technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patwardhan&rsquo;s shoulders first technique has been used successfully for difficult fetal extraction at cesarean in India [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/13\">",
"     13",
"    </a>",
"    ]. The technique involves first delivering the anterior shoulder and arm and then rotating the fetus and delivering the posterior shoulder and arm. The fetal trunk, breech, and lower limbs are then successively delivered through the incision using a combination of gentle traction on the arms, fingers beneath the thorax, and fundal pressure. Once the body is delivered, the head is lifted out of the pelvis in the same manner as a reverse breech extraction. Compared with the traditional abdominopelvic delivery technique, Patwardhan&rsquo;s technique has been reported to reduce the risk of uterine",
"    <span class=\"nowrap\">",
"     lacerations/extension",
"    </span>",
"    of the incision, bladder injuries, and need for blood transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vacuum extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors have described using the vacuum extractor to assist in delivering an impacted fetal head during cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, no one has described the technique clearly, specifically where the vacuum cup is applied. Given the difficulty of safely placing the vacuum cup in a standard fashion on an impacted fetal head, and the potential for both maternal and fetal trauma from this approach, we do not recommend that this technique be considered as a standard intervention. Severe fetal injuries, such as intracranial hemorrhage, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FLOATING HEAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the impacted fetal head, management of the \"floating\" or unengaged fetal head is a difficult problem. Unlike the impacted fetal head in which maternal structures can impede access to the head, the floating head is easily accessed, but difficult to control.",
"   </p>",
"   <p>",
"    In an uncomplicated cesarean delivery (see above), the head has typically advanced beyond the site of the hysterotomy and has to be gently elevated. Because the fetus becomes somewhat squeezed into the upper uterus, when the head is flexed toward the incision, uterine forces naturally push it along the path of least resistance, which is through the hysterotomy. The obstetrician's hand also acts as a guide.",
"   </p>",
"   <p>",
"    In contrast, when the head is floating above the hysterotomy incision, the uterus has already accommodated to the position of the fetus; therefore, uterine forces don't push it through the incision. The floating fetal head is difficult for the obstetrician to grasp or establish traction; it cannot readily be pulled and guided through the incision. Applying fundal pressure is often inadequate and has a tendency to push the head laterally rather than towards the hysterotomy.",
"   </p>",
"   <p>",
"    There are two relatively safe and easy options to alleviate the problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vacuum or forceps extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our preference is to place an obstetrical vacuum extractor over the flexion point (",
"    <a class=\"graphic graphic_figure graphicRef69870 \" href=\"UTD.htm?5/21/5456\">",
"     figure 7",
"    </a>",
"    ) to deliver the fetal head, as with any standard vaginal vacuum assisted delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. Unlike the impacted head, the flexion point of the floating head is accessible. Use of a soft, bell vacuum cup minimizes the risk of injury to the fetus and is a good choice because not much traction is needed since there should be minimal resistance to extraction. An equally simple method, used by the author, involves slipping a Coyne spoon into the uterus beneath the infant&rsquo;s cheek and using the leverage of the spoon to draw the infant&rsquo;s head into the hysterotomy (",
"    <a class=\"graphic graphic_movie graphicRef67734 \" href=\"UTD.htm?28/1/28690\">",
"     movie 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42903?source=see_link\">",
"     \"Procedure for vacuum assisted operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Forceps can also be used in this situation, depending on operator comfort and experience. One group described their use of Barton&rsquo;s forceps, which have a hinged anterior blade and sliding lock, for grasping a high vertex in transverse position [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11414/abstract/20\">",
"     20",
"    </a>",
"    ]. However, Barton&rsquo;s forceps are rarely used in contemporary obstetric practice, and should not be used to deliver a floating head by operators who are not experienced with their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Internal podalic version",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option is to perform internal podalic version and delivery of the fetus as a breech. The obstetrician reaches into the uterus with one hand, grasps one or both of the fetal feet and pulls them through the hysterotomy while guiding the head to the fundus with",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    other external hand. This technique causes the fetus to rotate from a vertex presentation to a footling breech presentation. As mentioned above, the operator should apply traction only parallel to the axis of the legs when grasping and pulling the feet, and should avoid hyperextension of the fetal neck. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Reverse breech extraction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXTREMELY LOW BIRTH WEIGHT INFANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremely low birth weight infants (premature or growth restricted) present many challenges at cesarean delivery. The uterus is less distended than with a term fetus and the lower uterine segment is less well-developed (thicker myometrium, smaller area). Thus, the hysterotomy incision is deeper and bloodier, and an adequate transverse incision to allow atraumatic extraction of the fetus may not be possible. It is also easy to inadvertently lacerate the fetus, especially in the setting of premature ruptured membranes, if the deepest layers if the myometrium are not incised carefully.",
"   </p>",
"   <p>",
"    Since these fetuses are premature",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    smaller, their bones and soft tissues are more delicate and prone to injury. The grasping and extraction pressures applied to these infants need to be significantly reduced to avoid iatrogenic damage.",
"   </p>",
"   <p>",
"    Also, because of the markedly reduced fetal size, the uterus is significantly smaller and occupies less of the abdomen and pelvis than larger, term pregnancies. As a result, the mother's intestines, which are usually confined to the upper abdomen in a cesarean delivery, frequently descend into the operative field and need to be manually displaced with either retractors or packing.",
"   </p>",
"   <p>",
"    To address all of the issues facing the cesarean delivery of the extremely premature or growth restricted fetus, obstetricians should carefully consider their choice and size of skin and uterine incisions. Although a low transverse skin incision (Pfannenstiel) is still a reasonable choice, surgeons should make sure that the skin incision length is adequate to provide all the exposure requirements one might encounter: the skin incision should not be prorated smaller to adjust for the smaller size of the infant.",
"   </p>",
"   <p>",
"    While some deliveries can be accomplished safely via a low transverse uterine incision, the lack of development of the lower uterine segment often precludes this option. A vertical uterine incision is frequently the more prudent choice and guarantees adequate access to the infant without the risks of head entrapment or injury to the uterine arteries. As with any incision, the surgeon's best judgment should ultimately dictate the choice.",
"   </p>",
"   <p>",
"    Decisions regarding route of delivery and whether to perform cesarean delivery because of the small fetal size are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20374?source=see_link\">",
"     \"Intrapartum management of the low birthweight vertex fetus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2022743\">",
"    <span class=\"h1\">",
"     BREECH OR TRANSVERSE LIE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery of the fetus in breech or transverse lie is described separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=see_link\">",
"       \"Delivery of the fetus in breech presentation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22662?source=see_link\">",
"       \"Management of the fetus in transverse lie\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For delivery of the impacted fetal head, we suggest abdominovaginal delivery or head elevators as a first-line approach, depending on the operator's level of comfort with each technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If unsuccessful, we try reverse breech extraction. We do not use vacuum devices in this setting. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Impacted head'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For delivery of the floating fetal head, we suggest vacuum or Coyne spoon extraction as a first-line approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If unsuccessful, we perform an internal podalic version. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Floating head'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/1\">",
"      Levy R, Chernomoretz T, Appelman Z, et al. Head pushing versus reverse breech extraction in cases of impacted fetal head during Cesarean section. Eur J Obstet Gynecol Reprod Biol 2005; 121:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/2\">",
"      Sung JF, Daniels KI, Brodzinsky L, et al. Cesarean delivery outcomes after a prolonged second stage of labor. Am J Obstet Gynecol 2007; 197:306.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/3\">",
"      Landesman R, Graber EA. Abdominovaginal delivery: modification of the cesarean section operation to facilitate delivery of the impacted head. Am J Obstet Gynecol 1984; 148:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/4\">",
"      Karasahin KE, Ercan M, Alanbay I, Baser I. Comment on 'Disengagement of the deeply engaged fetal head during cesarean section in advanced labor: conventional method versus reverse breech extraction'. Acta Obstet Gynecol Scand 2010; 89:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/5\">",
"      Lippert TH. Abdominovaginal delivery in case of impacted head in cesarean section operation. Am J Obstet Gynecol 1985; 151:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/6\">",
"      Lippert TH. Bimanual delivery of the fetal head at cesarean section with the fetal head in midcavity. Arch Gynecol 1983; 234:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/7\">",
"      Fasubaa OB, Ezechi OC, Orji EO, et al. Delivery of the impacted head of the fetus at caesarean section after prolonged obstructed labour: a randomised comparative study of two methods. J Obstet Gynaecol 2002; 22:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/8\">",
"      Tan EK. Difficult caesarean delivery of an impacted head and neonatal skull fracture: can the morbidity be avoided? J Obstet Gynaecol 2007; 27:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/9\">",
"      Fong YF, Arulkumaran S. Breech extraction--an alternative method of delivering a deeply engaged head at cesarean section. Int J Gynaecol Obstet 1997; 56:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/10\">",
"      Blickstein I. Difficult delivery of the impacted fetal head during cesarean section: intraoperative disengagement dystocia. J Perinat Med 2004; 32:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/11\">",
"      Tevet, A, Khatib, F, Finci, S. Reversed breech extraction maneuver for cesarean deliveries performed in the second stage of labor. SMFM Abstract. Am J Obstet Gynecol 2007; 197:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/12\">",
"      Chopra S, Bagga R, Keepanasseril A, et al. Disengagement of the deeply engaged fetal head during cesarean section in advanced labor: conventional method versus reverse breech extraction. Acta Obstet Gynecol Scand 2009; 88:1163.",
"     </a>",
"    </li>",
"    <li>",
"     Mukhopadhyay, P, Naskar, T, Dalui, R, Hazra, S, Bhattacharya, D, et al. Evaluation of Patwardhan&rsquo;s technic - a four year study in a rural teaching hospital. J Obstet Gynecol India 2005; 55:244.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/14\">",
"      Khosla AH, Dahiya K, Sangwan K. Cesarean section in a wedged head. Indian J Med Sci 2003; 57:187.",
"     </a>",
"    </li>",
"    <li>",
"     Apuzzio, JJ, Salamon, C. Cesarean setion. In: Operative obstetrics, 3rd ed, Apuzzio, JJ, Vintzileos, AM, Iffy, L (Eds), Francis &amp; Taylor Books, Co., London 2006. p.356.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/16\">",
"      Pelosi MA, Apuzzio J. Use of the soft, silicone obstetric vacuum cup for delivery of the fetal head at cesarean section. J Reprod Med 1984; 29:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/17\">",
"      Clark SL, Vines VL, Belfort MA. Fetal injury associated with routine vacuum use during cesarean delivery. Am J Obstet Gynecol 2008; 198:e4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/18\">",
"      Fareeduddin R, Schifrin BS. Subgaleal hemorrhage after the use of a vacuum extractor during elective cesarean delivery: a case report. J Reprod Med 2008; 53:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11414/abstract/19\">",
"      Arad I, Linder N, Bercovici B. Vacuum extraction at cesarean section--neonatal outcome. J Perinat Med 1986; 14:137.",
"     </a>",
"    </li>",
"    <li>",
"     Obican SG, Brunner M, Larsen JW. Barton's forceps: An effective aid in cesarean deliveries. Contemporary OBGYN 2011. file://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Bartons-forceps-An-effective-aid-in-cesarean-deliv/ArticleStandard/Article/detail/738940 (Accessed on September 21, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4450 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.196.66.12-750F5500E3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11414=[""].join("\n");
var outline_f11_9_11414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UNCOMPLICATED DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMPACTED HEAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abdominovaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fetal head elevators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Reverse breech extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18614340\">",
"      Patwardhan shoulders first technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vacuum extraction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FLOATING HEAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vacuum or forceps extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Internal podalic version",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXTREMELY LOW BIRTH WEIGHT INFANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2022743\">",
"      BREECH OR TRANSVERSE LIE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4450|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/13/31960\" title=\"figure 1\">",
"      Maylard incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/31/32242\" title=\"figure 2\">",
"      Uncomplicated cesarean delivery of fetus cephalic presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/10/23725\" title=\"figure 3\">",
"      Coyne spoon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/38/2670\" title=\"figure 4\">",
"      Sellheim spoon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/45/10975\" title=\"figure 5\">",
"      Murless head elevator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/32/29186\" title=\"figure 6\">",
"      Reverse breech extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/21/5456\" title=\"figure 7\">",
"      Flexion point fetal skull",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4450|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?28/1/28690\" title=\"movie 1\">",
"      Coyne spoon assisted delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=related_link\">",
"      Cesarean delivery: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21176?source=related_link\">",
"      Delivery of the fetus in breech presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20374?source=related_link\">",
"      Intrapartum management of the low birthweight vertex fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42952?source=related_link\">",
"      Management of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22662?source=related_link\">",
"      Management of the fetus in transverse lie",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42903?source=related_link\">",
"      Procedure for vacuum assisted operative vaginal delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_9_11415="Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)";
var content_f11_9_11415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11415/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11415/contributors\">",
"     Stephanie A Kaye-Barrett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11415/contributors\">",
"     Christopher P Denton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11415/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11415/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11415/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11415/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/9/11415/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 90 percent of patients with systemic sclerosis (SSc, scleroderma) have some degree of gastrointestinal (GI) involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The earliest visceral manifestation to be described is generally esophageal disease, which remains the most common source of GI symptoms in SSc, but any part of the gastrointestinal tract (mouth to anus) may be involved (",
"    <a class=\"graphic graphic_table graphicRef55280 \" href=\"UTD.htm?2/35/2621\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinically significant GI dysfunction occurs in approximately 50 percent, with severe involvement (such as malabsorption and intestinal pseudo-obstruction) being observed in less than 10 percent and portending a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Approximately 70 percent of patients die within three years of the onset of malabsorption, recurrent pseudo-obstruction, or the requirement for hyperalimentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of GI disease associated with SSc will be discussed here. The remaining issues relating to GI dysfunction, including pathogenesis, pathology, clinical manifestations, and diagnosis, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general management of GI manifestations is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef64498 \" href=\"UTD.htm?32/10/32940\">",
"     table 2",
"    </a>",
"    ). The appropriate therapy depends upon the location of involvement and resulting symptoms. It is important to recognize the nuances and subtleties of symptoms since small differences in presentation may result from entirely different pathogenetic mechanisms. As an example, intermittent diarrhea or constipation is most commonly due to intestinal dysmotility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pseudo-obstruction, while persistent diarrhea is likely to be secondary to malabsorption and bacterial overgrowth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OROPHARYNGEAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of oral manifestations of systemic sclerosis is largely supportive. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tight skin may be treated with facial exercises.",
"     </li>",
"     <li>",
"      Regular dental hygiene can help to prevent dental caries.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/59/37811?source=see_link\">",
"       Artificial saliva",
"      </a>",
"      may be used when patients also suffer from sicca syndrome.",
"     </li>",
"     <li>",
"      Surgical intervention includes \"mucosal advancement procedures,\" and some benefit from local injection to increase lip bulk in late-stage SSc has been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of esophageal disease is largely directed toward the amelioration of reflux, hypomotility, and the symptoms of strictures. The antisecretory drugs (for reflux) in combination with prokinetic agents (for hypomotility) are extremely useful in the treatment of these problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy of gastroesophageal reflux consists of lifestyle modifications such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Establishment of normal weight",
"     </li>",
"     <li>",
"      Elevation of the head of the bed",
"     </li>",
"     <li>",
"      Multiple small meals",
"     </li>",
"     <li>",
"      Avoidance of the supine position within three hours of eating",
"     </li>",
"     <li>",
"      Cessation of smoking and reduction of alcohol intake if excessive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to realize that calcium channel blockers and anticholinergic agents, which may be used to treat other manifestations of SSc, can potentially worsen reflux.",
"   </p>",
"   <p>",
"    The most effective drugs for the treatment of gastroesophageal reflux are the antisecretory agents, particularly the proton pump inhibitors.",
"   </p>",
"   <p>",
"    One study in patients with SSc found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    healed esophagitis and reduced elevated hydroxyproline levels to normal, suggesting some reversal of esophageal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/5\">",
"     5",
"    </a>",
"    ]. Although there are limited other data, omeprazole and other proton-pump inhibitors are the current drugs of choice for acid reflux since most patients are effectively controlled, for example, with omeprazole taken in a twice-daily dosing regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/6\">",
"     6",
"    </a>",
"    ]. The initial dose of omeprazole is 20 mg once daily; this can be increased to 20 mg twice daily or, in some patients, 40 mg twice daily, if necessary. These doses are generally well tolerated without serious side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/6\">",
"     6",
"    </a>",
"    ]. Other proton pump inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    ) are now being used, and trials are in progress to assess efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The H2 receptor blockers also reduce gastroesophageal reflux and improve symptoms and endoscopic evidence of esophagitis in patients with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/7\">",
"     7",
"    </a>",
"    ]. However, studies of reflux esophagitis in patients without SSc have shown that these drugs are generally less effective than the proton pump inhibitors. Sometimes the two classes of drug may be used in combination for refractory cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery for gastroesophageal reflux is relatively contraindicated in patients with hypomotility because it may result in severe dysphagia. Its use is generally limited to patients with severe, uncontrolled reflux. A Collis gastroplasty with fundoplication can significantly reduce gastroesophageal reflux in patients with SSc. In one study, for example, Collis surgery produced total relief of symptoms in 28 of 37 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/8\">",
"     8",
"    </a>",
"    ]. Unfortunately, the recurrence rate is high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypomotility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal hypomotility can be manifested as difficulty swallowing or a sensation of food being stuck in the throat. Prokinetic drugs such as cisapride and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    may relieve these symptoms in patients with SSc. These drugs act by increasing esophageal sphincter pressure, improving peristalsis, and enhancing gastric emptying (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Cisapride can be used at a dose of 10 to 20 mg four times daily and acts to release acetylcholine within the myenteric plexus. Although it has fewer overall side effects compared with metoclopramide, the risk of cardiac arrhythmias has prompted the manufacturer to severely restrict its availability in the United States; it remains available in several other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    may also be of benefit in this setting. It acts as a motilin agonist which increases gastric contractions and lowers esophageal sphincter pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/12\">",
"     12",
"    </a>",
"    ]. Studies suggest that high dose therapy can sometimes be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/12\">",
"     12",
"    </a>",
"    ]. A trial of erythromycin is reasonable if cisapride is ineffective. However, erythromycin should",
"    <strong>",
"     not",
"    </strong>",
"    be given in combination with cisapride. Erythromycin inhibits the cytochrome P-4503A4 enzyme, leading to reduced cisapride metabolism and a rise in serum cisapride levels. The latter can increase the risk of potentially fatal cisapride-induced torsade de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/11\">",
"     11",
"    </a>",
"    ]. Other drugs that have the same interaction are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and drugs in the imidazole class (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pill-induced esophagitis is more common in SSc due to decreased peristalsis. This may occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , tetracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and nonsteroidal antiinflammatory drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stricture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a stricture rather than hypomotility should be suspected in patients with severe dysphagia and regurgitation of liquids. Symptomatic strictures or mucosal rings can be dilated using Celestin or Eder Peustow dilators via esophagoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fungal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida may be treated with antifungal medication such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Cessation of therapy is associated with a high rate of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GASTRIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal manifestations of gastric involvement in SSc are those of delayed gastric emptying and bleeding. The treatment of delayed gastric emptying in patients with SSc is similar to the treatment of this problem in other patients. Dietary modification, antiemetics, and prokinetic agents may all be effective, although the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25476?source=see_link\">",
"     bethanechol",
"    </a>",
"    for delayed gastric emptying has been disappointing. Avoidance of solid food usually reduces the frequency of vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of upper GI bleeding due to telangiectasia consists of endoscopic coagulation of each lesion. Gastric resection may be considered if the telangiectasias are too numerous or are unresponsive to coagulation. Pulsed dye laser treatment or argon plasma coagulation is used, with the suggestion that complication rates are lower from argon plasma technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SMALL INTESTINAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of small bowel disease among patients with SSc largely consists of the management of malabsorption and steatorrhea, dysmotility, and recurrent pseudo-obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malabsorption in SSc is primarily due to small bowel bacterial overgrowth. It should be treated with oral antibiotics. The antibiotics are usually rotated (antibiotic change every four weeks with occasional \"antibiotic holiday\") since continuous therapy with one agent may result in the emergence of resistant organisms and an increased relapse rate. Successful treatment can be measured by a decrease in the frequency and fat content of the stools and by a negative glucose hydrogen breath test (if it had been previously positive). Cultured yogurt may help prevent relapsing infection.",
"   </p>",
"   <p>",
"    The choice of antibiotic may be made after the sensitivities of aspirated organisms are known. The choice is empiric when this information is not available or when the diagnosis is made on the basis of symptoms and a positive hydrogen breath test. In this setting, a number of antibiotics have been used, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    250 mg four times daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    with clavulanate 500 mg three times daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    200 mg twice daily, or an oral cephalosporin.",
"   </p>",
"   <p>",
"    Additional antibiotics have also been shown to be effective. In one study, for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    250 mg twice a day abolished diarrhea in all patients with established bacterial overgrowth and was found to be more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/13\">",
"     13",
"    </a>",
"    ]. One patient with severe bacterial overgrowth continued on ciprofloxacin for 18 months (three week courses without rotating antibiotics) without the emergence of resistance (unpublished data). When diarrhea recurs in a patient still on antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    can be added for five to seven days to treat anaerobic flora.",
"   </p>",
"   <p>",
"    The length of therapy and degree of antibiotic rotation required for symptom remission may vary. Some patients with less severe overgrowth go into remission for many months after a 7 to 10 day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or other standard antibiotic. Others with severe persistent diarrhea require the rotation of antibiotics for 7 to 21 days per month. One rotation regimen consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      (250 mg four times daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      (200 mg twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (250 mg twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      (500 mg three times daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      , as a possible addition for five to seven days if breakthrough occurs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dysmotility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prokinetic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , cisapride and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ) have had only anecdotal success in treating small bowel dysmotility and malabsorption. In our practice, their use has been disappointing.",
"   </p>",
"   <p>",
"    A single study has reported success in treating five patients with 50 &micro;g of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (a long-acting somatostatin analogue) administered subcutaneously at bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11415/abstract/14\">",
"     14",
"    </a>",
"    ]. Octreotide caused an average of 3.6 migrating motor complexes in three hours of small bowel recordings when there had previously been none. In addition, breath hydrogen fell from an average of 25 to 4 ppm. We have used this drug in two patients and found no diminution of symptoms or of breath hydrogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pseudo-obstruction and small bowel failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of recurrent pseudo-obstruction and severe small bowel failure presents many challenges. Although prokinetic agents can be tried,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    may be necessary in patients who are already malnourished due to chronic bacterial overgrowth. As a result, a permanent central feeding line may need to be inserted for intermittent or continuous use.",
"   </p>",
"   <p>",
"    Enteral feeding may require percutaneous gastrostomy or jejunostomy. The latter may be advantageous especially if gastroesophageal reflux is problematic. For parenteral feeding, a permanent central feeding line needs to be inserted for intermittent or continuous use. Careful management of feeding lines is critically important, as scleroderma patients may be especially susceptible to infection and other local complications.",
"   </p>",
"   <p>",
"    Home parenteral nutrition has been successfully performed in a small number of our patients who were unable to maintain a satisfactory body weight. It can also be used intermittently for episodes of pseudo-obstruction or weight loss. Long-term survival has been reported in this setting, but serious complications such as central venous thrombosis and sepsis can occur. A venting enterostomy is an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    in patients in whom some bowel function is preserved and in whom the degree of malnutrition is less critical.",
"   </p>",
"   <p>",
"    Abdominal surgery should be avoided if at all possible for pseudo-obstruction for two primary reasons: adhesions may confuse the subsequent diagnoses of pseudo-obstruction, and the SSc tends to affect the bowel in a diffuse manner. Resection is, therefore, not generally useful.",
"   </p>",
"   <p>",
"    When pseudo-obstruction is in remission, the patient should be restricted to a lactose-free, low fiber diet. Fat should also be replaced as much as possible with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    . Some patients require intramuscular injections of vitamin B12 and oral supplements of fat- and water-soluble vitamins, calcium, and iron.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pneumatosis cystoides intestinalis and pneumoperitoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless there are signs of peritonitis, pneumatosis cystoides intestinalis and pneumoperitoneum should be treated conservatively. For most asymptomatic patients, reduction of substrates such as lactose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , fructose, and fiber will promote cyst resolution. Since the disease involves trapping of gas and cyst formation in the gut wall due to fermentation, medical treatment in symptomatic patients also consists of oxygen therapy plus antibiotics to reduce the number of gas forming bacteria. If available, hyperbaric oxygen can be used in severe or resistant cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31223?source=see_link\">",
"     \"Pneumatosis intestinalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COLONIC AND ANORECTAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of colon and anorectal disorders in systemic sclerosis is largely aimed toward the alleviation of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fecal incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although diarrhea is principally due to small bowel bacterial overgrowth, its presence may contribute significantly to the development of fecal incontinence. As a result, incontinence associated with diarrhea should be treated with antibiotics in combination with nonspecific measures including a low residue diet, antidiarrheal agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    ), and bile acid-binding resins (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    ). Biofeedback and posterior anal repair (if proximal colonic material is normal) may also be tried. Local injection of synthetic biopolymer may improve sphincter function in carefully selected cases. Good results have been reported using implanted sacral nerve stimulators. Sacral nerve neuromodulation by a temporary or long-term electrical stimulator can be helpful in selected cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prokinetic agents can be tried for constipation, although they are unlikely to be successful. Surgery to relieve outflow obstruction may have a role when the delay is localized to the rectosigmoid colon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     BILIARY TREE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hepatobiliary disease among patients with SSc largely involves the management of primary biliary cirrhosis and is primarily supportive. It includes the management of metabolic bone disease, pruritus, and deficiencies of fat-soluble vitamins.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of the bone disease, which can be manifest as either osteoporosis or osteomalacia, consists of calcium supplementation (total intake of 1500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and vitamin D supplementation in patients who have evidence of vitamin D deficiency (eg, low plasma levels of calcidiol, a hepatic metabolite of vitamin D that is the precursor of calcitriol formation in the kidney). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=see_link\">",
"       \"Metabolic bone disease in primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with pruritus respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"       colestipol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=see_link\">",
"       \"Pruritus associated with cholestasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin E is also likely to be deficient and must be replaced.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       Ursodiol",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      ) may be beneficial in slowing the rate of progression of primary biliary cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=see_link\">",
"       \"Overview of the treatment of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with advanced cirrhosis should be considered for hepatic transplantation unless precluded by the severity of their SSc. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27430?source=see_link\">",
"       \"Liver transplantation in primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PANCREATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with steatorrhea who fail to respond to antibiotic therapy for overgrowth should be investigated for pancreatic insufficiency using a para-amino benzoic acid test. If pancreatic insufficiency is confirmed, therapy with enzyme supplements or nutrizyme should be initiated. A sample regimen consists of three Creon capsules per meal and one with snacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4473279\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Choice of therapy for gastrointestinal (GI) manifestations of systemic sclerosis (SSc, scleroderma) depends upon the location of involvement, the underlying mechanism, and the resulting symptoms. We perform a careful evaluation, as conditions requiring different interventions may result in only subtle differences in presentation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use largely supportive therapies for oral manifestations of SSc, including facial exercises for tight skin, attentive dental care, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/59/37811?source=see_link\">",
"       artificial saliva",
"      </a>",
"      and other interventions for sicca symptoms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Oropharyngeal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We manage esophageal disease with a primary focus on the amelioration of reflux, hypomotility, and the symptoms of strictures; oral and esophageal candidiasis is treated with antifungal agents. We treat reflux with both lifestyle modifications, such as bed elevation and avoidance of late meals, and antisecretory agents, usually a proton pump inhibitor.",
"      <br/>",
"      <br/>",
"      In patients with hypomotility, we use prokinetic drugs, such as cisapride or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      , and avoid nonsteroidal antiinflammatory drugs or calcium channel blockers, if possible. Coadministration of cisapride with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , or imidazoles should be avoided because of potentially fatal drug interactions. Treatment for esophageal strictures involves use of both proton pump inhibitors and dilatation when needed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Esophageal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use prokinetic agents in patients with delayed gastric emptying, but many patients do not respond and benefit from avoidance of solid foods. In patients with gastric telangiectasias, endoscopic procedures may be required. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Gastric disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We treat malabsorption from small bowel bacterial overgrowth with oral antibiotics. Patients with intestinal pseudo-obstruction and small bowel failure may require parenteral nutrition and dietary modification. Prokinetic agents are generally not effective in such patients or in those with dysmotility of the small bowel. Pneumatosis cystoides intestinalis and pneumoperitoneum should be treated conservatively, unless there are signs of peritonitis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Small intestinal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of colon and anorectal disorders in systemic sclerosis is largely aimed towards the alleviation of symptoms. Diarrhea may contribute significantly to the development of fecal incontinence, although it is principally due to small bowel bacterial overgrowth. Incontinence associated with diarrhea should thus be treated with antibiotics in combination with nonspecific measures including a low residue diet, antidiarrheal agents, and bile acid-binding resins. Some patients benefit from biofeedback, posterior anal repair or other procedures, or sacral nerve stimulation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Colonic and anorectal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with steatorrhea who fail to respond to antibiotic therapy for overgrowth should be investigated for pancreatic insufficiency, which we treat with enzyme supplements or nutrizyme. In patients with primary biliary cirrhosis, which may occur in patients with SSc, we provide supportive therapies for the management of metabolic bone disease, pruritus, and deficiencies of fat-soluble vitamins and additional evaluation and intervention as indicated. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pancreatic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Biliary tree disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=see_link\">",
"       \"Overview of the treatment of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/1\">",
"      Turner R, Lipshutz W, Miller W, et al. Esophageal dysfunction in collagen disease. Am J Med Sci 1973; 265:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/2\">",
"      Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989; 28:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/3\">",
"      Cohen S. The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology 1980; 79:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/4\">",
"      Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/5\">",
"      Hendel L. Hydroxyproline in the oesophageal mucosa of patients with progressive systemic sclerosis during omeprazole-induced healing of reflux oesophagitis. Aliment Pharmacol Ther 1991; 5:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/6\">",
"      Hendel L, Hage E, Hendel J, Stentoft P. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992; 6:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/7\">",
"      Hendel L, Aggestrup S, Stentoft P. Long-term ranitidine in progressive systemic sclerosis (scleroderma) with gastroesophageal reflux. Scand J Gastroenterol 1986; 21:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/8\">",
"      Orringer MB, Orringer JS, Dabich L, Zarafonetis CJ. Combined Collis gastroplasty--fundoplication operations for scleroderma reflux esophagitis. Surgery 1981; 90:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/9\">",
"      Kahan A, Chaussade S, Gaudric M, et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharmacol 1991; 31:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/10\">",
"      Horowitz M, Maddern GJ, Maddox A, et al. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 1987; 93:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/11\">",
"      Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/12\">",
"      Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther 2004; 19:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/13\">",
"      Kaye SA, Lim SG, Taylor M, et al. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol 1995; 34:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11415/abstract/14\">",
"      Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325:1461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7556 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11415=[""].join("\n");
var outline_f11_9_11415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4473279\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OROPHARYNGEAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ESOPHAGEAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypomotility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fungal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GASTRIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SMALL INTESTINAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dysmotility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pseudo-obstruction and small bowel failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pneumatosis cystoides intestinalis and pneumoperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COLONIC AND ANORECTAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      BILIARY TREE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PANCREATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4473279\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7556|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/35/2621\" title=\"table 1\">",
"      GI symptoms in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/10/32940\" title=\"table 2\">",
"      Rx GI disorders in scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27430?source=related_link\">",
"      Liver transplantation in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=related_link\">",
"      Metabolic bone disease in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31223?source=related_link\">",
"      Pneumatosis intestinalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_9_11416="Clinical manifestations, diagnosis, and treatment of osteomalacia";
var content_f11_9_11416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of osteomalacia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11416/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11416/contributors\">",
"     CJ Menkes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11416/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11416/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/9/11416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia is a disorder of bone, characterized by decreased mineralization of newly formed osteoid at sites of bone turnover. Several different disorders cause osteomalacia via mechanisms that result in hypocalcemia, hypophosphatemia, or direct inhibition of the mineralization process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will present an overview of the clinical manifestations, diagnosis, and treatment of adults with osteomalacia. The treatment of nutritional, hereditary vitamin D resistant, and pseudovitamin D-deficient rickets in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169580\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29575908\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia may be asymptomatic and present radiologically as osteopenia. It can also produce characteristic symptoms, independently of the underlying cause, including diffuse bone and joint pain, muscle weakness, and difficulty walking [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a report of 17 patients with osteomalacia on bone biopsy, the following findings were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone pain and muscle weakness in 16 (94 percent)",
"     </li>",
"     <li>",
"      Bone tenderness in 15 (88 percent)",
"     </li>",
"     <li>",
"      Fracture in 13 (76 percent)",
"     </li>",
"     <li>",
"      Difficulty walking and waddling gait in four (24 percent)",
"     </li>",
"     <li>",
"      Muscle spasms, cramps, a positive Chvostek&rsquo;s sign,",
"      <span class=\"nowrap\">",
"       tingling/numbness,",
"      </span>",
"      and inability to ambulate in one to two (6 to 12 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms may be insidious in onset. Bone pain is usually most pronounced in the lower spine, pelvis, and lower extremities, where fractures have taken place, and may be associated with tenderness to palpation. The pain is characterized as dull and aching and is aggravated by activity and weight bearing. Fractures may occur with little or no trauma, typically involving the ribs, vertebrae, and long bones. Abnormal spinal curvature or deformity of the thorax or pelvis appears only in severe osteomalacia of long duration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The muscle weakness characteristically is proximal and may be associated with muscle wasting, hypotonia, and discomfort with movement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/1\">",
"     1",
"    </a>",
"    ]. There may also be a waddling gait. It is likely that high levels of parathyroid hormone (PTH) and low levels of phosphate and calcitriol all contribute to the myopathy, since similar findings occur in primary hyperparathyroidism.",
"   </p>",
"   <p>",
"    Osteomalacia secondary to hypophosphatasia is associated with poorly healing metatarsal fractures or chondrocalcinosis and premature loss of teeth during childhood.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15280944\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory abnormalities in osteomalacia are largely dependent upon the cause of the osteomalacia (",
"    <a class=\"graphic graphic_table graphicRef65400 \" href=\"UTD.htm?15/57/16284\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and etiology of osteomalacia\", section on 'Etiologic diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In retrospective reviews of patients with biopsy-proven nutritional osteomalacia, the following laboratory abnormalities were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alkaline phosphatase elevated in 95 to 100 percent",
"     </li>",
"     <li>",
"      Serum calcium and phosphorus reduced in 27 to 38 percent",
"     </li>",
"     <li>",
"      Urinary calcium low in 87 percent",
"     </li>",
"     <li>",
"      25-hydroxyvitamin D (calcidiol) &lt;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in 100 percent",
"     </li>",
"     <li>",
"      PTH elevated in 100 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of patients (40 of 43) in this review had nutritional osteomalacia from either a gastrointestinal disorder or suboptimal nutrition and inadequate sun exposure. In these cases, 25-hydroxyvitamin D levels were very low (&lt;10",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    25",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    which differentiates vitamin D deficiency from the other causes of osteomalacia, such as the renal phosphate wasting syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169587\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiological abnormalities in adults who develop osteomalacia are less striking than those seen in children with rickets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .) Reduced bone density with thinning of the cortex is the most common finding but it is very nonspecific. More specific are changes in vertebral bodies and Looser zones. Infrequently, radiologic evidence of secondary hyperparathyroidism can be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169594\">",
"    <span class=\"h3\">",
"     Changes in vertebral bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate mineralization of osteoid and loss of secondary trabeculae lead to a loss of radiologic distinctness of vertebral body trabeculae, making the x-ray appear of poor quality (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56149 \" href=\"UTD.htm?0/22/352\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87021 \" href=\"UTD.htm?4/12/4289\">",
"     image 2",
"    </a>",
"    ). With more advanced disease, softening leads to a concavity of the vertebral bodies called codfish vertebrae. The vertebral disks appear large and biconvex. There may be spinal compression fractures, but these are more common in osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169601\">",
"    <span class=\"h3\">",
"     Looser zones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Looser pseudofractures, fissures, or narrow radiolucent lines, 2 to 5 mm in width with sclerotic borders, are the characteristic radiologic finding in osteomalacia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52768 \" href=\"UTD.htm?7/43/7862\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/6\">",
"     6",
"    </a>",
"    ]. They often are bilateral and symmetric and lie perpendicular to the cortical margins of bones. They are usually found at the femoral neck, on the medial part of the femoral shaft, immediately under the lesser trochanter or a few centimeters beneath, and in the pubic and ischial rami. They may also occur at the ulna, scapula, clavicle, rib, and metatarsal bones. Pseudofractures can also be seen with bone scans where they appear as hot spots [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/7\">",
"     7",
"    </a>",
"    ]. The term \"Milkman syndrome\" refers to the combination of multiple bilateral and symmetric pseudofractures in a patient with osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Looser zones have been postulated to represent either [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress fractures that have been repaired by the laying down of inadequately mineralized osteoid, or",
"     </li>",
"     <li>",
"      Erosion of bone by arterial pulsations, since they often lie in apposition to arteries",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169608\">",
"    <span class=\"h3\">",
"     Secondary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal changes induced by long-standing secondary hyperparathyroidism are less frequent than the above abnormalities. When they do occur, they include subperiosteal resorption of the phalanges, bone cysts, and resorption of the distal ends of long bones such as the clavicle and humerus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H196421#H196421\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Skeletal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169615\">",
"    <span class=\"h3\">",
"     Other x-ray findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;More severe osteomalacia can lead to shortening and bowing of the tibia, pathologic fractures, coxa profunda hip deformity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79529 graphicRef57357 \" href=\"UTD.htm?28/56/29569\">",
"     image 4A-B",
"    </a>",
"    ), and cephalopelvic disproportion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87020 \" href=\"UTD.htm?17/52/18240\">",
"     image 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22949458\">",
"    <span class=\"h2\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated markedly reduced spine, hip, and forearm bone density (as measured by dual-energy x-ray absorptiometry [DXA]) in patients with osteomalacia related to vitamin D deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, bone mineral density (BMD) is not required for the diagnosis of osteomalacia, and bone mineral density (DXA) findings are unable to differentiate osteomalacia and osteoporosis.",
"   </p>",
"   <p>",
"    In contrast, BMD tends to be normal or increased (especially lumbar spine) in adults with X-linked hypophosphatemic rickets (XLH), axial osteomalacia, fibrogenesis imperfecta, and skeletal fluorosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. This discrepancy may be related in part to differences in parathyroid hormone values in the two groups (high in vitamin D deficiency and normal in the others).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29575819\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia should be suspected in cases of bone pain associated with malabsorption, gastric bypass surgery, celiac sprue, chronic hepatic disease, or chronic kidney disease. The diagnosis is based on a combination of clinical features (bone pain, tenderness, fractures, muscle weakness), laboratory results, radiologic findings and, rarely, bone histomorphometry.",
"   </p>",
"   <p>",
"    Clinical evaluation, including history of gastrointestinal diseases or procedures, sun exposure, dietary habits, onset (insidious or acute) and duration of symptoms, may help determine the etiology of osteomalacia. Laboratory abnormalities in osteomalacia are largely dependent on its cause (",
"    <a class=\"graphic graphic_table graphicRef65400 \" href=\"UTD.htm?15/57/16284\">",
"     table 1",
"    </a>",
"    ), and therefore laboratory findings are used to diagnose and determine the etiology of osteomalacia. The initial laboratory evaluation should include measurement of serum concentrations of calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D (25OHD), parathyroid hormone, electrolytes, BUN, and creatinine.",
"   </p>",
"   <p>",
"    Radiographs may be helpful in certain settings (eg, severe bone pain), to distinguish osteomalacia from multiple myeloma or Paget disease of bone. Bone biopsy and histomorphometry should be performed only when the diagnosis of osteomalacia is in doubt or the cause of osteomalacia is not determined by noninvasive testing, eg, to assess for one of the rare disorders of defective bone matrix, such as axial osteomalacia or fibrogenesis imperfecta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology and etiology of osteomalacia\", section on 'Defective bone matrix'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A delay in diagnosis of osteomalacia is commonly reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. In one study of 33 women with osteomalacia, the mean duration of symptoms before diagnosis was 2.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/14\">",
"     14",
"    </a>",
"    ]. Diagnoses considered prior to confirmation of osteomalacia included osteoporosis, Paget&rsquo;s disease, malignancy, pseudohypoparathyroidism, osteoarthritis, malabsorption, irritable bowel syndrome with depression, and somatization disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H231457703\">",
"    <span class=\"h2\">",
"     Interpretation of laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the laboratory evaluation is to distinguish vitamin D deficiency or resistance from the phosphate wasting syndromes and other less common causes of osteomalacia (",
"    <a class=\"graphic graphic_table graphicRef65400 \" href=\"UTD.htm?15/57/16284\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In nutritional osteomalacia, 25-hydroxyvitamin D (25OHD, calcidiol) is typically very low, &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (25",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      calcium and phosphate low to low-normal, and parathyroid hormone and alkaline phosphatase high [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/1\">",
"       1",
"      </a>",
"      ]. The serum concentration of 1,25-dihydroxyvitamin D may be normal, low, or high, depending upon the severity and duration of vitamin D deficiency, and is therefore not helpful in making the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In primary renal phosphate wasting, serum phosphate is low and phosphate clearance is elevated. Serum 1,25-dihydroxyvitamin D levels are frequently inappropriately normal for the degree of hypophosphatemia (1,25-dihydroxyvitamin D should increase in response to severe hypophosphatemia). Serum calcium and 25OHD levels are normal, and parathyroid hormone and alkaline phosphatase levels are normal or mildly elevated. Patients may also have other tubular defects (hypouricemia, aminoaciduria, and glucosuria) if the phosphate wasting is part of a generalized Fanconi syndrome. Heavy metals in the urine may be increased if they are the cause of the Fanconi's syndrome. In patients with tumor-induced osteomalacia and hereditary hypophosphatemic rickets, fibroblast growth factor (FGF) 23 may be elevated [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"       \"Causes of hypophosphatemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In type 2 (proximal) renal tubular acidosis, there is a hyperchloremic metabolic acidosis and hypophosphatemia. The latter reflects both proximal phosphate wasting and secondary hyperparathyroidism due to acidosis-induced hypercalciuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H4#H4\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In hypophosphatasia, the alkaline phosphatase level is low while the serum calcium and phosphate concentrations are normal. Reduced activity of the alkaline phosphatase enzyme results in accumulation of substrates, including phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5&rsquo;-phosphate (PLP), in blood and urine. In patients not taking a vitamin B6 (pyridoxine) supplement, elevated plasma PLP is a marker of hypophosphatasia. Mutational analysis of the tissue-nonspecific isoenzyme of alkaline phosphatase is available commercially [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link&amp;anchor=H17#H17\">",
"       \"Epidemiology and etiology of osteomalacia\", section on 'Hypophosphatasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In fibrogenesis imperfecta and axial osteomalacia, alkaline phosphatase, calcium, phosphate, and vitamin D are usually normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link&amp;anchor=H18#H18\">",
"       \"Epidemiology and etiology of osteomalacia\", section on 'Defective bone matrix'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In skeletal fluorosis, serum calcium and phosphate are usually normal, and alkaline phosphate is elevated. Serum, urine, and bone fluoride content is increased [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27833579\">",
"    <span class=\"h2\">",
"     Bone biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone biopsy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    labeling is the most accurate way to diagnose osteomalacia. However, it is infrequently performed clinically because it is invasive and because the diagnosis can usually be made from a combination of clinical and laboratory findings. The histomorphometric characteristics of osteomalacia include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged mineralization lag time",
"     </li>",
"     <li>",
"      Widened osteoid seams",
"     </li>",
"     <li>",
"      Increased osteoid volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these features are necessary for the diagnosis, because other disorders may show one of these findings. Wide osteoid seams reflecting high turnover, for example, can be seen with hyperthyroidism, Paget's disease, and hyperparathyroidism. However, the mineral apposition rate is elevated in these disorders in contrast to the low values in osteomalacia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of osteomalacia\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of bone fractures, bone pain, and reduced bone mineral density include osteoporosis, malignancy, Paget&rsquo;s disease, and hyperparathyroidism. Most of these diagnoses can be distinguished from osteomalacia by the clinical history, physical examination, and a combination of laboratory and radiologic studies. Bone biopsy using double",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    labeling (assuming that the patient is not allergic to tetracycline) is performed rarely, reserved for cases that are difficult to diagnose using noninvasive methods [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoporosis occurs in different settings from osteomalacia, particularly postmenopausal women, elderly subjects, and patients treated with chronic corticosteroid therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"       \"Osteoporotic fracture risk assessment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"       \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Osteoporosis is characterized by normal serum levels of calcium, phosphate, and alkaline phosphatase. This is in contrast to the frequent findings of one or more of the following in the different causes of osteomalacia: hypophosphatemia, hypocalcemia, low levels of 25-hydroxyvitamin D (&lt;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [25",
"      <span class=\"nowrap\">",
"       nmol/L]),",
"      </span>",
"      and increased parathyroid hormone and alkaline phosphatase levels (",
"      <a class=\"graphic graphic_table graphicRef65400 \" href=\"UTD.htm?15/57/16284\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/20\">",
"       20",
"      </a>",
"      ]. Although 25-hydroxyvitamin D levels may be low in patients with osteoporosis, and a subset of these patients may also have secondary elevations of parathyroid hormone, 25OHD levels rarely are below 10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (25",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H15280944\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Reduced bone mineral density does not distinguish osteoporosis from osteomalacia. Patients with osteomalacia due to vitamin D deficiency may have markedly reduced spine, hip, and forearm bone density. In such patients, treatment with bisphosphonates, teriparatide, or other osteoporosis medications is not appropriate and may exacerbate hypocalcemia. Osteomalacia related to vitamin D deficiency should be treated with vitamin D and calcium, which often results in marked improvement in BMD. (See",
"      <a class=\"local\" href=\"#H4071500\">",
"       'Vitamin D deficiency'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients with Paget disease of bone, alkaline phosphatase is elevated, but bone scan and radiographic findings are unique. Plain radiographs of involved areas reveal cortical thickening, expansion, coarsening of trabecular markings and mixed areas of lucency and sclerosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with multiple myeloma, weakness, fatigue, and bone pain are common. Conventional radiographs often reveal lytic lesions, as well as diffuse osteopenia and vertebral fractures. Many patients have anemia and abnormal renal function at diagnosis, whereas patients with osteomalacia generally have normal renal function. Alkaline phosphatase is usually not elevated in multiple myeloma, and hypercalcemia may be present in some patients. Multiple myeloma is a common cause of type 2 renal tubular acidosis in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with hyperparathyroidism, both PTH and calcium are elevated, whereas calcium levels are either low or normal in osteomalacia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"       \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7669805\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of osteomalacia should be directed at reversal of the underlying disorder, if possible, and correction of hypophosphatemia, hypocalcemia, and vitamin D deficiency.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4071500\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D supplementation in patients who are deficient in this hormone leads to a dramatic improvement in muscle strength and bone tenderness within weeks. Bone density may improve within three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/5\">",
"     5",
"    </a>",
"    ]. Multiple preparations of vitamin D and its metabolites are available. Vitamin D, rather than its metabolites, is used when possible since the cost is modest. Vitamin D metabolites are required when there is abnormal vitamin D metabolism (liver or renal disease). The recommended preparation and dose vary with the clinical condition.",
"   </p>",
"   <p>",
"    With each regimen, the serum calcium concentration and urinary calcium excretion are monitored, initially after one month and three months, and then less frequently (every 6 to 12 months), until 24-hour urinary calcium excretion is normal. The serum calcium concentration is monitored to permit early detection of hypercalcemia from excessive dosing. Serum 25-hydroxyvitamin D should be measured approximately three to four months after initiating therapy. The dose should be adjusted to prevent hypercalciuria or hypercalcemia. In most cases, serum calcium and phosphate are normal after a few weeks of treatment, but alkaline phosphatase remains elevated for several months. Healing of osteomalacia is considered to have occurred when there are increases in urinary calcium excretion and bone density. Healing may take many months to a year and varies with the degree and duration of the deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to vitamin D supplementation, all patients should maintain a calcium intake of at least 1000 mg per day, since inadequate intake of calcium may contribute to the development of osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The combination of calcium and vitamin D is more likely to produce radiographic evidence of nearly complete healing of rickets (58 versus 19 percent in Nigerian children with nutritional rickets) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/23\">",
"     23",
"    </a>",
"    ]. A higher calcium dose (up to 4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    may be necessary in patients with malabsorption.",
"   </p>",
"   <p>",
"    The treatment of vitamin D deficiency is reviewed in detail separately and briefly summarized here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Vitamin D repletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no standard dosing regimen for treating vitamin D deficiency. One common approach is to treat nutritional deficiency (25OHD &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [50",
"      <span class=\"nowrap\">",
"       nmol/L])",
"      </span>",
"      with 50,000 international units (units) of vitamin D2 or D3 orally once per week for six to eight weeks, and then 800 units of vitamin D3 daily thereafter. However, the efficacy of this practice, compared with daily, weekly, or monthly dosing, has not been rigorously established.",
"     </li>",
"     <li>",
"      In malabsorptive states, oral dosing and duration of treatment depend upon the vitamin D absorptive capacity of the individual patient. Doses of vitamin D of 10,000 to 50,000 units daily may be necessary to replete patients with gastric bypass or malabsorption. Patients who remain deficient or insufficient on such doses will need to be treated with hydroxylated vitamin D metabolites (calcidiol or calcitriol) because they are more readily absorbed, or with sun or sunlamp exposure.",
"     </li>",
"     <li>",
"      In liver disease, the vitamin D metabolite, calcidiol (25-hydroxyvitamin D), should be used because it does not require hepatic 25-hydroxylation. The onset of action is more rapid and the half-life of two to three weeks is shorter than that of vitamin D3 and similar to that of vitamin D2. The dose in this situation is 50 to 200",
"      <span class=\"nowrap\">",
"       micrograms/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Calcidiol is not readily available in the United States, so calcitriol may be used in patients with severe liver disease who remain deficient after treatment with vitamin D2 or vitamin D3.",
"     </li>",
"     <li>",
"      Calcitriol (1,25-dihydroxyvitamin D) is a vitamin D metabolite available in capsules of 0.25 and 0.5 micrograms. It has a rapid onset of action and the half-life is only six hours. It is associated with a fairly high incidence of hypercalcemia and patients should be followed carefully. It is most useful in those with decreased synthesis of calcitriol, as occurs in chronic renal failure or in type 1 vitamin D-dependent rickets (due to an inactivating mutation in the 1-hydroxylase gene). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H12#H12\">",
"       \"Etiology and treatment of calcipenic rickets in children\", section on 'Vitamin D dependent rickets type I'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dihydrotachysterol is available as tablets of 0.125, 0.2, and 0.5 mg. It is functionally equivalent to 1alpha-hydroxyvitamin D. It requires hepatic 25-hydroxylation prior to becoming therapeutically active. DHT can be used in the disorders for which calcitriol is used. It has a rapid onset of action, and a relatively short duration of action.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4071584\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hereditary and acquired renal phosphate wasting syndromes, renal osteodystrophy, and renal tubular acidosis are discussed in greater detail elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary hypophosphatemic rickets is treated with a combination of phosphate supplementation and calcitriol. Tumor-induced osteomalacia is treated similarly until the causative tumor can be removed, or indefinitely if tumor removal is not possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In renal insufficiency, both oral and intravenous calcitriol can be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteomalacia of renal tubular acidosis is treated initially with 5000 to 10,000 units per day of vitamin D. The acidosis is corrected with sodium",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      potassium citrate. Once the bone heals, supraphysiologic doses of vitamin D (above 800",
"      <span class=\"nowrap\">",
"       units/day)",
"      </span>",
"      should not be necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link\">",
"       \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For hypophosphatasia or the rare skeletal disorders of defective bone matrix (axial osteomalacia and fibrogenesis imperfecta), there are no established therapies. In a preliminary report, infusion of recombinant human tissue-nonspecific isoenzyme of alkaline phosphatase was associated with improvement in skeletal radiographs, pulmonary, and physical function in infants and young children [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients with axial osteomalacia do not appear to deteriorate over time. In contrast, patients with fibrogenesis imperfecta develop severe skeletal pain, debilitating fractures, and progressive immobility [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11416/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link&amp;anchor=H17#H17\">",
"       \"Epidemiology and etiology of osteomalacia\", section on 'Hypophosphatasia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link&amp;anchor=H18#H18\">",
"       \"Epidemiology and etiology of osteomalacia\", section on 'Defective bone matrix'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4483926\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of osteomalacia may include bone pain and tenderness, muscle weakness, difficulty walking, and a waddling gait. Laboratory findings depend upon the underlying cause of osteomalacia (",
"      <a class=\"graphic graphic_table graphicRef65400 \" href=\"UTD.htm?15/57/16284\">",
"       table 1",
"      </a>",
"      ). Typical laboratory features of nutritional osteomalacia include elevations in alkaline phosphatase and PTH, and decreases in calcium, phosphate, and 25-hydroxyvitamin D concentrations. (See",
"      <a class=\"local\" href=\"#H3169580\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15280944\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic radiologic findings are Looser pseudofractures, fissures, or narrow radiolucent lines. In addition, inadequate mineralization of osteoid and loss of secondary trabeculae lead to a loss of radiologic distinctness of the vertebral body trabeculae and concavity of the vertebral bodies (codfish vertebrae). Bone mineral density (BMD) is not required for the diagnosis of osteomalacia, and reduced BMD does not distinguish osteoporosis from osteomalacia. However, several studies have demonstrated markedly reduced spine, hip, and forearm bone density (as measured by dual-energy x-ray absorptiometry [DXA]) in patients with osteomalacia related to vitamin D deficiency. (See",
"      <a class=\"local\" href=\"#H3169587\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteomalacia should be suspected in cases of bone pain associated with malabsorption, gastric bypass surgery, celiac sprue, chronic hepatic disease, or chronic kidney disease. The diagnosis is based upon a combination of clinical features (bone pain, tenderness, and fractures, muscle weakness), laboratory results (",
"      <a class=\"graphic graphic_table graphicRef65400 \" href=\"UTD.htm?15/57/16284\">",
"       table 1",
"      </a>",
"      ), radiologic findings and, rarely, bone histomorphometry. (See",
"      <a class=\"local\" href=\"#H29575819\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory abnormalities in osteomalacia are largely dependent on its cause (",
"      <a class=\"graphic graphic_table graphicRef65400 \" href=\"UTD.htm?15/57/16284\">",
"       table 1",
"      </a>",
"      ), and therefore laboratory findings are used to diagnose and determine the etiology of osteomalacia. Laboratory evaluation should include measurement of serum concentrations of calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D (25OHD), parathyroid hormone, electrolytes, BUN, and creatinine. Radiographs may be helpful in certain settings (severe bone pain), to distinguish osteomalacia from multiple myeloma or Paget disease of bone. Bone biopsy and histomorphometry should be performed only when the diagnosis of osteomalacia is in doubt or the cause of osteomalacia is not determined with noninvasive testing, eg, to assess for one of the rare disorders of defective bone matrix. (See",
"      <a class=\"local\" href=\"#H29575819\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of osteomalacia depends upon the underlying etiology. For patients with osteomalacia secondary to severe vitamin D deficiency, vitamin D repletion leads to a dramatic improvement in muscle strength and bone tenderness within weeks. Many clinicians treat nutritional deficiency (25-hydroxyvitamin D &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [50",
"      <span class=\"nowrap\">",
"       nmol/L])",
"      </span>",
"      with 50,000 units of vitamin D2 or D3 orally once per week for six to eight weeks, followed by a maintenance dose (eg, 800 units of vitamin D3 daily) thereafter. (See",
"      <a class=\"local\" href=\"#H4071500\">",
"       'Vitamin D deficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of vitamin D deficiency in adults\", section on 'Dosing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After initiation of vitamin D treatment, the serum calcium concentration and urinary calcium excretion are monitored, first after one month and three months, and then less frequently (every 6 to 12 months). The serum calcium concentration is monitored to permit early detection of hypercalcemia from excessive dosing. Serum 25-hydroxyvitamin D should be measured approximately three to four months after initiating therapy. The dose should be adjusted to prevent adverse effects of hypercalciuria or hypercalcemia. Biological and radiological abnormalities may take up to one year to disappear. (See",
"      <a class=\"local\" href=\"#H4071500\">",
"       'Vitamin D deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary hypophosphatemic rickets is treated with a combination of phosphate supplementation and calcitriol. Tumor-induced osteomalacia is treated similarly until the causative tumor can be removed, or indefinitely if tumor removal is not possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lips P, van Schoor NM, Bravenboer N. Vitamin D-related disorders. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th, Rosen CJ, Compston JE, Lian JB (Eds), American Society for Bone and Mineral Research, Washington, DC 2008. p.329.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/2\">",
"      Gifre L, Peris P, Monegal A, et al. Osteomalacia revisited : a report on 28 cases. Clin Rheumatol 2011; 30:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/3\">",
"      Bhan A, Rao AD, Rao DS. Osteomalacia as a result of vitamin D deficiency. Endocrinol Metab Clin North Am 2010; 39:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/4\">",
"      Basha B, Rao DS, Han ZH, Parfitt AM. Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. Am J Med 2000; 108:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/5\">",
"      Bhambri R, Naik V, Malhotra N, et al. Changes in bone mineral density following treatment of osteomalacia. J Clin Densitom 2006; 9:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/6\">",
"      Frame B, Parfitt AM. Osteomalacia: current concepts. Ann Intern Med 1978; 89:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/7\">",
"      Kim S, Park CH, Chung YS. Hypophosphatemic osteomalacia demonstrated by Tc-99m MDP bone scan: a case report. Clin Nucl Med 2000; 25:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/8\">",
"      Milkman, LA. Multiple spontaneous idiopathic symmetrical fractures. Am J Roentgenol 1934; 32:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/9\">",
"      Steinbach, HL, Kolb, FO, Crane, JT. Unusual roentgen manifestations of osteomalacia. Am J Roentgenol 1959; 82:863.",
"     </a>",
"    </li>",
"    <li>",
"     Goldring SR, Krane SM. Disorders of calcification: Osteomalacia and rickets. In: Endocrinology, DeGroot LJ (Ed), Grune &amp; Stratton, New York 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/11\">",
"      Rosenthall L. DEXA bone densitometry measurements in adults with X-linked hypophosphatemia. Clin Nucl Med 1993; 18:564.",
"     </a>",
"    </li>",
"    <li>",
"     Whyte, MP. Sclerosing Bone Disorders. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Seventh Edition, Rosen CJ (Ed), American Society of Bone and Mineral Research, Washington, DC 2008. p.412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/13\">",
"      Kurland ES, Schulman RC, Zerwekh JE, et al. Recovery from skeletal fluorosis (an enigmatic, American case). J Bone Miner Res 2007; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/14\">",
"      de Torrent&eacute; de la Jara G, P&eacute;coud A, Favrat B. Female asylum seekers with musculoskeletal pain: the importance of diagnosis and treatment of hypovitaminosis D. BMC Fam Pract 2006; 7:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/15\">",
"      Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007; 22:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/16\">",
"      Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 2008; 42:1235.",
"     </a>",
"    </li>",
"    <li>",
"     Whyte, MP. Enzyme defects and the skeleton. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Seventh Edition, Rosen CJ (Ed), The American Society of Bone and Mineral Research, Washington, DC 2008. p.454.",
"    </li>",
"    <li>",
"     Parfitt, AM. Vitamin D and the pathogenesis of rickets and osteomalacia. In: Vitamin D, second edition, Feldman D, Pike JW, Glorieux FH (Eds), Elsevier Academic Press, San Diego 2005. p.1029.",
"    </li>",
"    <li>",
"     Recker, RR. Bone biopsy and histomorphometry in clinical practice. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, Seventh Edition, Rosen CJ (Ed), American Society of Bone and Mineral Research, Washington, DC 2008. p.180.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/20\">",
"      Bingham CT, Fitzpatrick LA. Noninvasive testing in the diagnosis of osteomalacia. Am J Med 1993; 95:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/21\">",
"      Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 1995; 43:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/22\">",
"      Allen SC, Raut S. Biochemical recovery time scales in elderly patients with osteomalacia. J R Soc Med 2004; 97:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/23\">",
"      Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med 1999; 341:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/24\">",
"      Bishop N. Rickets today--children still need milk and sunshine. N Engl J Med 1999; 341:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11416/abstract/25\">",
"      Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2012; 366:904.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2040 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11416=[""].join("\n");
var outline_f11_9_11416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4483926\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3169580\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29575908\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15280944\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3169587\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3169594\">",
"      - Changes in vertebral bodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3169601\">",
"      - Looser zones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3169608\">",
"      - Secondary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3169615\">",
"      - Other x-ray findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22949458\">",
"      Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29575819\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H231457703\">",
"      Interpretation of laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27833579\">",
"      Bone biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7669805\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4071500\">",
"      Vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4071584\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4483926\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2040|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/22/352\" title=\"diagnostic image 1\">",
"      Blurred spine in osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/12/4289\" title=\"diagnostic image 2\">",
"      Osteomalacia of the lumbar spine CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/43/7862\" title=\"diagnostic image 3\">",
"      Pseudofractures in osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/22/26990\" title=\"diagnostic image 4A\">",
"      Tibial bowing in osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/0/19471\" title=\"diagnostic image 4B\">",
"      Coxa profunda in osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/52/18240\" title=\"diagnostic image 5\">",
"      Cephalopelvic disproportion in osteomalacia radiographic finding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/57/16284\" title=\"table 1\">",
"      Lab findings in osteomalacia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_9_11417="Managing multiple comorbidities";
var content_f11_9_11417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Managing multiple comorbidities",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11417/contributors\">",
"     Heather E Whitson, MD, MHS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11417/contributors\">",
"     Cynthia M. Boyd, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11417/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11417/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/9/11417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30994423\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multimorbidity, or multiple comorbidity, is common and greatly increases the complexity of managing disease in older patients. Among Medicare patients in the United States, it is estimated that one-third have four or more chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/1\">",
"     1",
"    </a>",
"    ], and more than half of older adults have three or more chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the particular challenges posed by managing patients with multiple comorbidities and present strategies to maximize effective care for such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30629397\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multimorbidity refers to the co-occurrence of two or more medical or psychiatric conditions, which may or may not directly interact with each other within the same individual [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The term &ldquo;multimorbidity&rdquo; is sometimes used interchangeably with comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/6\">",
"     6",
"    </a>",
"    ], but comorbidity technically indicates a condition or conditions that coexist in the context of an index disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, an oncologist may be concerned with the effect of comorbidity on the management of lung cancer, whereas multimorbidity captures the general complexity of patients without focusing on any single disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multimorbidity includes traditional diseases and syndromes such as heart disease, diabetes, rheumatologic conditions, chronic pulmonary disease, and dementia. The concept is often extended to include other common chronic conditions such as constipation, chronic bursitis, falls, sleep disturbances, or sensory impairments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30629384\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although exact prevalence estimates depend on the type and number of conditions considered in the definition of multimorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], most experts agree that more than one in four Americans have at least two chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Similarly, a study in Scotland found multimorbidity in 23 percent of the 1.75 million people included in a database from over 300 medical practices [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the prevalence of many diseases rises with age, multimorbidity is increasingly common throughout the lifespan, affecting about 15.0 percent of Americans between ages 20 to 44 years, 35.3 percent of Americans aged 65 to 79 years, and 70.2 percent of Americans aged 80 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately two-thirds of Medicare beneficiaries over age 65 have two or more chronic conditions, and approximately one-third have four or more [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/1\">",
"     1",
"    </a>",
"    ]. Due to the aging of the population and to advances in medical care and public health that have allowed people to live longer with incurable diseases, the number and proportion of patients with multiple chronic conditions are growing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/3,14\">",
"     3,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to age, lower socioeconomic status is also associated with a higher prevalence of multimorbidity. In the cross-sectional Scottish study, the age of multimorbidity onset was lower (by 10 to 15 years) among individuals living in the most deprived, compared to the most affluent, areas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because certain conditions heighten the risk of developing other conditions, people with multimorbidity are likely to accumulate more diagnoses and experience escalating clinical complexity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. In one study that analyzed data from over 60,000 adults in the Netherlands and adjusted for age and insurance status, individuals with multimorbidity at baseline were 40 percent more likely than those without multimorbidity to be diagnosed with two or more new conditions during the next year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the US National Health and Nutrition Examination Survey (NHANES) found that among 1259 individuals with coronary heart disease who were surveyed, coexisting noncardiac morbidities included arthritis (57 percent), chronic lung disease (25 percent), diabetes (25 percent), renal insufficiency (24 percent), and stroke (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/17\">",
"     17",
"    </a>",
"    ]. Functional issues included urinary incontinence (49 percent), mobility difficulty (40 percent), falls or dizziness (35 percent), and cognitive impairment (30 percent). The majority of patients (55 percent) were taking four or more medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994430\">",
"    <span class=\"h1\">",
"     IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multimorbidity is associated with staggering healthcare utilization and costs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. The two-thirds of Medicare beneficiaries with multimorbidity account for 96 percent of Medicare expenditures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with multiple chronic conditions are at heightened risk of significant adverse health outcomes, often beyond the effects of the individual conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/15,19-31\">",
"     15,19-31",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Death",
"     </li>",
"     <li>",
"      Functional limitation and disability",
"     </li>",
"     <li>",
"      Frailty (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28792?source=see_link\">",
"       \"Frailty\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nursing home placement",
"     </li>",
"     <li>",
"      Diminished quality of life",
"     </li>",
"     <li>",
"      Treatment complications",
"     </li>",
"     <li>",
"      Avoidable inpatient admissions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994437\">",
"    <span class=\"h1\">",
"     PATIENT CARE CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most treatments and practice guidelines target a single index condition, but patients with multimorbidity are complex and heterogeneous. The traditional disease-focused approach to clinical medicine may render care that is fragmented and poorly coordinated and produce treatment plans that are inefficient, ineffective, or even harmful for patients with multimorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/8,17,20,32-35\">",
"     8,17,20,32-35",
"    </a>",
"    ]. Currently, clinicians have limited guidance or evidence on which to base care decisions for such patients. In focus group interviews, primary care clinicians in the United States identified multiple issues in providing care for patients with multimorbidity, including insufficient data about best practices, inadequate support and collaboration with specialists, conflicts between clinician and patient priorities, and reimbursement policies that don&rsquo;t adequately compensate for the effort involved in the management of complex patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994444\">",
"    <span class=\"h2\">",
"     Adherence to multiple clinical practice guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical practice guidelines are developed with the intent to address the diagnosis or management of a single clinical entity. The challenges and potential harm brought about by rigid adherence to clinical practice guidelines in patients with multimorbidity is illustrated in a paper that examined the hypothetical case of a 79-year-old woman with hypertension, diabetes mellitus, osteoporosis, osteoarthritis, and chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/34\">",
"     34",
"    </a>",
"    ]. In following the most inexpensive and simple treatment plan that would satisfy all guidelines, the hypothetical patient would need to take 12 medications (costing $406 per month in 2005) and, each year, follow 14 recommendations related to self-care or education, diagnostic testing, or referrals to other specialists or services (",
"    <a class=\"graphic graphic_table graphicRef69591 \" href=\"UTD.htm?22/32/23053\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81404 \" href=\"UTD.htm?42/8/43148\">",
"     table 2",
"    </a>",
"    ). Furthermore, different guidelines may offer conflicting recommendations (eg, weight-bearing exercise recommended by the osteoporosis guideline conflicts with cautions in weight-bearing for neuropathic patients in the diabetes guideline) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the applicability of most clinical practice guidelines to patients with multimorbidity is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], there are some that do recognize the need to adapt recommendations for patients with increased complexity. As an example, the California Health",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Geriatrics Society&rsquo;s guidelines for the management of older patients with diabetes advocate for prioritization of goals of care among multiple conditions and recommend more permissive targets for glycemic control and blood pressure among patients with frailty or limited life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994451\">",
"    <span class=\"h2\">",
"     Competing demands and shifting priorities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to competing demands are common when caring for patients with multiple conditions. Patients with multimorbidity typically experience a fluctuating health status, with particular ailments rotating into and out of the forefront in terms of their influence on the patient&rsquo;s overall well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To maximize quality of life, patients with multimorbidity must strike a daily balance between attending to their health problems, thereby controlling symptoms and reducing flares and complications while avoiding the potential for their lives to be ruled by the demands of chronic disease management [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/39\">",
"     39",
"    </a>",
"    ]. Clinicians&rsquo; well-meaning attempts to aggressively treat all conditions all the time, without sufficient attention to the whole person and his or her shifting priorities, may result in treatment recommendations that the patient finds overwhelming, unaffordable, or otherwise unrealistic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians themselves must balance competing demands for their time in attempting to address multiple health issues within the confines of a 15- to 20-minute office visit. By time constraints alone, a primary care provider in the United States with a standard patient panel may be unable to deliver the services currently recommended for chronic disease management and prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The situation is compounded when a treatment beneficial for one condition (eg, anticoagulation for atrial fibrillation) may lead to harm due to a concurrent condition (eg, bleeding from diverticulosis), forcing a prioritization of competing health objectives. Similarly, patients with multimorbidity and the clinicians who provide their care must prioritize conditions that require the most active management and balance treatment strategies consistent with the patient&rsquo;s preferences, tolerance, and needs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994459\">",
"    <span class=\"h2\">",
"     Polypharmancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to a 2010 CDC report, 37 percent of older Americans use five or more prescription drugs each month and medication use in the United States, which has doubled since 1999, continues to rise [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients with more chronic conditions and more frequent clinical encounters take more medicines and are at the greatest risk of being prescribed potentially inappropriate medications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even when each medication has an appropriate indication, polypharmacy is associated with burden, cost, and risk of drug-drug or drug-condition interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The important issue of polypharmacy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=see_link&amp;anchor=H18186995#H18186995\">",
"     \"Drug prescribing for older adults\", section on 'Polypharmacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994466\">",
"    <span class=\"h2\">",
"     Limited evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major challenge in delivering appropriate care to patients with multimorbidity stems from the fact that these complex patients are under-represented in clinical research populations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/33,47\">",
"     33,47",
"    </a>",
"    ]. Comorbidities typically are an exclusion factor for patient recruitment into studies addressing a given clinical condition. When investigators do attempt to include representative numbers of patients with multimorbidity in a clinical trial, they often face challenges in terms of recruitment and retention that lead to selection bias and large amounts of missing data [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, the evidence base to guide medical decision-making for these patients is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/34\">",
"     34",
"    </a>",
"    ]. In the absence of trial data, providers cannot be certain how the presence of coexisting conditions may alter the tolerance or treatment effect of an intervention for a particular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the heterogeneous nature of multimorbidity makes it difficult to control for confounding or to draw inferences about how a broad array of coexisting conditions may have impacted treatment effect [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994473\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT WITH MULTIMORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several strategies for managing the challenges of caring for patients with multimorbidity, and opportunities to improve care, have emerged from research in this area. A systematic review of 10 trials to improve outpatient management of patients with multimorbidities found that a variety of multidimensional and often multidisciplinary interventions had mixed results, with trends toward improvement in medication adherence and prescribing practices [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/52\">",
"     52",
"    </a>",
"    ]. Interventions that focused on patient-specific risk factors or functional difficulties were more effective. &nbsp;",
"   </p>",
"   <p>",
"    A panel convened by the American Geriatric Society (AGS) has identified five guiding principles for management of multimorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elicit and incorporate patient preferences into medical decision-making.",
"     </li>",
"     <li>",
"      Recognize the limitations of the evidence base in interpreting and applying the medical literature to older adults with multimorbidity.",
"     </li>",
"     <li>",
"      Frame clinical management decisions within the context of risks, burdens, benefits, and prognosis (remaining life expectancy, functional status, quality of life).",
"     </li>",
"     <li>",
"      Consider treatment complexity and feasibility when making clinical management decisions.",
"     </li>",
"     <li>",
"      Choose therapies that optimize benefit, minimize harm, and enhance the quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef86695 \" href=\"UTD.htm?22/38/23151\">",
"     algorithm 1",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    We have attempted to highlight key aspects of care delivery for this population that promote coordinated, safe, high-quality care that are in keeping with patient preferences and feasible within the current healthcare system, consistent with the AGS guiding principles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994480\">",
"    <span class=\"h2\">",
"     Elicit patient goals and priorities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Institute of Medicine&rsquo;s report, &ldquo;Crossing the Quality Chasm,&rdquo; emphasized that the &ldquo;true north&rdquo; of quality in healthcare is the patient experience [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/53\">",
"     53",
"    </a>",
"    ]. This becomes all the more relevant for patients with multimorbidity, given the challenges of conflicting recommendations, competing demands, and limited evidence.",
"   </p>",
"   <p>",
"    To optimize care for the individual patient, a provider must understand the patient&rsquo;s goals and preferences and how his or her health relates to perceived roles within a family or community [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The dialogue about patient goals and priorities includes a discussion of end-of-life preferences, as well as medical decision-making to include drug initiation and discontinuation, hospitalizations and procedures, receipt of preventive services, and recommendations for behavioral changes such dietary restrictions and frequency of blood pressure monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful elicitation of patient preference requires that the patient and provider communicate effectively and that the patient has an adequate understanding of relevant choices and their expected outcomes. It is important to recognize that patients with multimorbidity frequently have impairments in hearing, vision, or cognition that may restrict communication or their capacity to process information. Special measures may be necessary to overcome the barriers associated with these impairments (",
"    <a class=\"graphic graphic_table graphicRef58401 \" href=\"UTD.htm?23/38/24172\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Even in patients without known communication barriers, there is considerable variability in individual&rsquo;s comfort level and desire to engage in the medical decision-making process [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/56\">",
"     56",
"    </a>",
"    ]. Approaches to enhancing patient involvement need to be flexible. Factors implicated in successful patient engagement include communication skills of the provider, trust in the relationship, and adequate time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/56\">",
"     56",
"    </a>",
"    ]. When available, a referral for Comprehensive Geriatric Assessment may be a useful means of clarifying goals and priorities for patients with multimorbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=see_link\">",
"     \"Comprehensive geriatric assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994487\">",
"    <span class=\"h2\">",
"     Coordination of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multimorbidity experience frequent clinical encounters, often with multiple providers representing different disciplines across many healthcare settings (including outpatient, inpatient, emergency department, long-term or rehabilitation facilities, and in-home care) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/53,57\">",
"     53,57",
"    </a>",
"    ]. Transitions of care have been identified as a high-risk opportunity for medical errors, particularly for complex patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12330?source=see_link&amp;anchor=H16#H16\">",
"     \"Hospital discharge\", section on 'Failed handoffs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inconsistent recommendations or duplicative care from various providers can result in patient confusion, unnecessary cost, and treatment burden [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. An essential component of high-quality care for patients with multimorbidity is coordination of a uniform care plan that is communicated across settings, providers, and caregivers.",
"   </p>",
"   <p>",
"    Electronic health records are helpful in coordinating care because they facilitate access to and sharing of information between various providers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. For particularly complex medical decisions, direct communication among providers, patients, and caregivers is often the best means of filling in knowledge gaps or arriving at a consensus. Multidisciplinary forums, such as Tumor Boards or Stroke Teams, may provide regular opportunities for discussion of patients by multiple providers involved in a certain aspect of patient care.",
"   </p>",
"   <p>",
"    The time constraints of most clinical practices and the fragmented, disease-focused nature of service provision make it challenging to coordinate an overall care plan effectively in the current healthcare system. Case managers and extended care providers may play an essential role in coordinating care for the most complicated and vulnerable patients within a practice [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the value of informal, unpaid caregivers (family and friends) is increasingly recognized, particularly in the care of patients with multimorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/67\">",
"     67",
"    </a>",
"    ]. Nonprofessional caregivers influence adherence and decision-making, supplement self-care, and frequently accompany patients to office visits [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Although questions remain about how to optimally engage and integrate this support network, such caregivers are often instrumental in managing &ldquo;the big picture&rdquo; for patients with multimorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Innovative models show promise in their ability to promote more seamless, efficient, and holistic care for older adults with multimorbidity. These programs often incorporate many aspects of the Wagner Chronic Care model, which emphasizes system elements that promote coordinated care by creating partnerships among patients, their families and informal caregivers, and providers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Examples of these models of care include Guided Care [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/74-76\">",
"     74-76",
"    </a>",
"    ], the Program of All-Inclusive Care of the Elderly (PACE) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/77\">",
"     77",
"    </a>",
"    ], Geriatric Resources for Assessment and Care of Elders (GRACE) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/78\">",
"     78",
"    </a>",
"    ], and the Patient-Centered Medical Home [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Integrated care, involving both psychiatric and medical specialty providers, to address the medical conditions and depression that frequently coexist in older patients with chronic medical problems can improve quality of life and disability outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994494\">",
"    <span class=\"h2\">",
"     Less may be best",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every intervention, hospitalization, or medication prescribed creates the potential for harm. These risks are magnified in patients with multimorbidity. Careful consideration should be given to each treatment decision and how it figures into the patient&rsquo;s preferences and overall equation of potential benefit versus burden and risk.",
"   </p>",
"   <p>",
"    In the management of older patients with diabetes, guidelines from the California Health",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Geriatrics Society recognize the need to prioritize goals of care for patients with multiple conditions and recommend more permissive targets for glycemic control and blood pressure among patients with frailty or limited life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/38\">",
"     38",
"    </a>",
"    ]. Similarly, there is increasing attention to the need to ensure that preventive practices remain relevant and appropriate for patients with multiple chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Cancer screening in patients with limited life expectancy is associated with unfavorable risk to benefit ratios, and screening should be discontinued in patients with less than a five-year life expectancy or in those who would decline treatment if disease is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Importantly, the decision to cease screening or other preventive care in this population should be based upon patient preference and life expectancy, which can be estimated from considerations of age and health status [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link&amp;anchor=H614882#H614882\">",
"     \"Screening for breast cancer\", section on 'Combining age with other variables'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link&amp;anchor=H21#H21\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Screening in older adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link&amp;anchor=H39#H39\">",
"     \"Screening for prostate cancer\", section on 'Stopping screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize inappropriate prescribing and adverse drug reactions in patients with multimorbidity, we recommend the following general strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Start low, go slow with any medication initiation or dose change.",
"     </li>",
"     <li>",
"      Always ask, &ldquo;Can this problem or symptom be addressed without my prescription pad?&rdquo; For example:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Can sleep disturbance be addressed with sleep hygiene and behavioral changes?",
"     </li>",
"     <li>",
"      Could incontinence be addressed with scheduled voiding and referral to urogynecological rehabilitation specialist?",
"     </li>",
"     <li>",
"      Could reflux be addressed with dietary changes and elevation of the head of the bed?",
"     </li>",
"     <li>",
"      Can ankle edema be addressed with leg elevation and compression stockings?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent review of medication list for appropriateness in the context of patient&rsquo;s current goals and preferences.",
"     </li>",
"     <li>",
"      Consolidate drug dosing schedules to minimize complexity and chance of error. The Institute of Medicine has proposed a standardized schedule for specifying medication dosing (morning, noon, evening, bedtime), recognizing that 90 percent of prescriptions are taken four or fewer times daily [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consolidate treatments when possible (ie, ACE inhibitor for blood pressure, renal protection, and heart failure).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30994501\">",
"    <span class=\"h2\">",
"     Identify and address issues that impact multiple conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;One efficient way to promote better outcomes for patients with multimorbidity is to identify issues that affect a patient&rsquo;s well-being or quality of life in ways that cut across many diseases. Examples of these issues include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nutrition",
"     </li>",
"     <li>",
"      Physical",
"      <span class=\"nowrap\">",
"       activity/exercise",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Function/independence",
"      </span>",
"     </li>",
"     <li>",
"      Sleep disturbance",
"     </li>",
"     <li>",
"      Mental health",
"     </li>",
"     <li>",
"      Safety of environment and adequacy of support in current level of care",
"     </li>",
"     <li>",
"      Caregiver stress [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624058\">",
"    <span class=\"h2\">",
"     Common disease-specific considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even in patients with multimorbidity, it is sometimes appropriate to apply typical management strategies to individual chronic conditions. For example, aggressive management of heart failure may be necessary to prevent exacerbations and frequent hospitalizations. Patients with a history of myocardial infarction (MI) should receive a trial of beta blockers, even in the setting of comorbid chronic obstructive pulmonary disease (COPD), because many patients with COPD tolerate beta blockers and the treatment benefit of beta blockers post-MI is clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the presence of comorbidity frequently dictates the need to adjust the treatment plans for individual conditions. Due to the heterogeneity of comorbidities that may coexist with any condition, it is not feasible to provide a uniform set of guidelines for the management of a specific disease in patients with multimorbidity. The guiding principle in patients with multimorbidity should be individualization of treatment. We have highlighted frequent considerations that arise in the setting of two common comorbidities, which may justify departure from rigid adherence to disease-specific guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624113\">",
"    <span class=\"h3\">",
"     Diabetes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A target hemoglobin A1c (A1C) of 8 percent is appropriate in persons with limited life expectancy or persons in whom the risks of hypoglycemia outweigh the benefit of more aggressive targets [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/38\">",
"       38",
"      </a>",
"      ]. As an example, the risk of hypoglycemia may be elevated in persons who have difficulty maintaining consistent caloric intake due to gastrointestinal comorbidities or conditions that cause frequent nausea or anorexia.",
"     </li>",
"     <li>",
"      Insulin therapy may be inappropriate in patients with cognitive or visual impairments that increase the risk of medication error, unless the patient has a caregiver with the ability to assist with every insulin dose.",
"     </li>",
"     <li>",
"      The risk of hypoglycemia is increased in older adults, particularly those with comorbidities. Thus, when possible, therapeutic agents should be selected that have a lower risk for hypoglycemia (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , shorter-acting sulfonylurea, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"       repaglinide",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The value of self-monitoring blood glucose (SMBG) in patients with type 2 diabetes who are diet-treated or treated with oral agents that are not associated with hypoglycemia is not as clear as for other diabetic patients. Thus, advice regarding SMBG for older diabetic patients, and especially those with comorbidity, should be tailored to the patient, based upon medications and functional and cognitive abilities.",
"     </li>",
"     <li>",
"      Electrolytes and renal function should be assessed within one to two weeks of initiation or dose adjustments of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), or diuretics, due to the increased likelihood of adverse effects in patients with multimorbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11417/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=see_link\">",
"     \"Treatment of type 2 diabetes mellitus in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624140\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should receive nonpharmacologic therapy, particularly dietary salt restriction and weight loss in obese patients. Drug therapy should be started if lifestyle changes are not sufficient.",
"     </li>",
"     <li>",
"      Blood pressure should be reduced gradually, by no more than 20 mmHg at a time.",
"     </li>",
"     <li>",
"      Tolerance to blood pressure reduction should be assessed at regular intervals with attention to orthostasis postprandial hypotension, falls, and activity restriction due to dizziness. More permissive blood pressure targets are appropriate, if patient preferences favor quality of life over potential benefit of additional blood pressure reduction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Goal blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Comorbidities should guide choice of agent. The goal is to avoid exacerbating comorbid conditions (eg, discontinue beta blockers if they worsen reactive airway disease or diuretics if they exacerbate urinary incontinence) and to minimize polypharmacy (eg, choose an alpha blocker to simultaneously address benign prostatic hypertrophy and hypertension, rather than prescribing a separate medication for each condition).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/18/11554?source=see_link\">",
"       \"Patient information: When you have depression and another health problem (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/34/32290?source=see_link\">",
"       \"Patient information: Taking medicines when you're older (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/36/27202?source=see_link\">",
"       \"Patient information: When you have multiple health problems (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30020203\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multimorbidity, the co-occurrence of two or more medical or psychiatric conditions, occurs in patients of all ages and is increasingly prevalent with advancing age, affecting 70 percent of Americans over age 80 years. It is associated with poor health outcomes and significant healthcare expenditures. (See",
"      <a class=\"local\" href=\"#H30629384\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30994430\">",
"       'Impact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The challenges of managing patients with multimorbidity are multiple, including the lack of guidelines that are applicable to these complex patients and the conflicting recommendations that arise in trying to apply guidelines developed for single disease entities; competing and shifting patient priorities of conditions to be addressed; the risks associated with polypharmacy; and lack of evidence on how best to treat patients with specific comorbid illnesses. (See",
"      <a class=\"local\" href=\"#H30994437\">",
"       'Patient care challenges'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Principles of caring for patients with multiple morbidities include attention to understanding a patients goals of treatment and healthcare priorities; communication between the multiple providers, healthcare facilities, and caregivers involved in a patient&rsquo;s treatment; recognizing the potential harms associated with medical interventions and minimizing drug dosing and complexity; and identifying and addressing lifestyle and psychosocial issues that may affect the patient&rsquo;s quality of life and response to medical care. (See",
"      <a class=\"local\" href=\"#H30994473\">",
"       'Approach to the patient with multimorbidity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Chronic Conditions: Making the case for ongoing care. September 2004 update. Johns Hopkins and the Robert Wood Johnson Foundation's Partnership for Solutions. Available at: file://www.partnershipforsolutions.org/DMS/files/chronicbook2004.pdf (Accessed on October 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/2\">",
"      Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc 2012; 60:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/3\">",
"      Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 2008; 14 Suppl 1:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/4\">",
"      Fortin M, Hudon C, Haggerty J, et al. Prevalence estimates of multimorbidity: a comparative study of two sources. BMC Health Serv Res 2010; 10:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/5\">",
"      Mercer SW, Smith SM, Wyke S, et al. Multimorbidity in primary care: developing the research agenda. Fam Pract 2009; 26:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/6\">",
"      Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/7\">",
"      Yancik R, Ershler W, Satariano W, et al. Report of the national institute on aging task force on comorbidity. J Gerontol A Biol Sci Med Sci 2007; 62:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/8\">",
"      Boyd CM, Fortin M. Future of multimorbidity research: How should understanding of multimorbidity inform health system design? Public Health Reviews 2010; 32:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/9\">",
"      Boyd CM, Ritchie CS, Tipton EF, et al. From Bedside to Bench: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Comorbidity and Multiple Morbidity in Older Adults. Aging Clin Exp Res 2008; 20:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/10\">",
"      Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases--a systematic review on existing multimorbidity indices. J Gerontol A Biol Sci Med Sci 2011; 66:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/11\">",
"      van den Akker M, Buntinx F, Roos S, Knottnerus JA. Problems in determining occurrence rates of multimorbidity. J Clin Epidemiol 2001; 54:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/12\">",
"      Fortin M, Bravo G, Hudon C, et al. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005; 3:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/13\">",
"      Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380:37.",
"     </a>",
"    </li>",
"    <li>",
"     Multiple Chronic Conditions: A Strategic Framework - Optimum Health and Quality of Life for Individuals with Multiple Chronic Conditions. US Deptartment of Health and Human Services 2010. Available at: file://www.hhs.gov/ash/initiatives/mcc/mcc_framework.pdf (Accessed on October 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/15\">",
"      Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/16\">",
"      van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998; 51:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/17\">",
"      Boyd CM, Leff B, Wolff JL, et al. Informing clinical practice guideline development and implementation: prevalence of coexisting conditions among adults with coronary heart disease. J Am Geriatr Soc 2011; 59:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/18\">",
"      Thorpe KE, Ogden LL, Galactionova K. Chronic conditions account for rise in Medicare spending from 1987 to 2006. Health Aff (Millwood) 2010; 29:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/19\">",
"      Ettinger WH, Davis MA, Neuhaus JM, Mallon KP. Long-term physical functioning in persons with knee osteoarthritis from NHANES. I: Effects of comorbid medical conditions. J Clin Epidemiol 1994; 47:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/20\">",
"      Fortin M, Soubhi H, Hudon C, et al. Multimorbidity's many challenges. BMJ 2007; 334:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/21\">",
"      Fillenbaum GG, Pieper CF, Cohen HJ, et al. Comorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortality. J Gerontol A Biol Sci Med Sci 2000; 55:M84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/22\">",
"      Fried LP, Bandeen-Roche K, Kasper JD, Guralnik JM. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol 1999; 52:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/23\">",
"      Cornoni-Huntley JC, Foley DJ, Guralnik JM. Co-morbidity analysis: a strategy for understanding mortality, disability and use of health care facilities of older people. Int J Epidemiol 1991; 20 Suppl 1:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/24\">",
"      Fortin M, Bravo G, Hudon C, et al. Relationship between multimorbidity and health-related quality of life of patients in primary care. Qual Life Res 2006; 15:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/25\">",
"      Menotti A, Mulder I, Nissinen A, et al. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 2001; 54:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/26\">",
"      Grau L, Kovner C. Comorbidity, age, and hospital use among elderly Medicare patients. J Aging Health 1991; 3:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/27\">",
"      Marengoni A, von Strauss E, Rizzuto D, et al. The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. J Intern Med 2009; 265:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/28\">",
"      Glynn LG, Valderas JM, Healy P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract 2011; 28:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/29\">",
"      Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes 2009; 7:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/30\">",
"      Whitson HE, Cousins SW, Burchett BM, et al. The combined effect of visual impairment and cognitive impairment on disability in older people. J Am Geriatr Soc 2007; 55:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/31\">",
"      Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med 2007; 22 Suppl 3:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/32\">",
"      Tinetti ME, Fried T. The end of the disease era. Am J Med 2004; 116:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/33\">",
"      Parekh AK, Barton MB. The challenge of multiple comorbidity for the US health care system. JAMA 2010; 303:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/34\">",
"      Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/35\">",
"      Fried TR, Tinetti ME, Iannone L. Primary care clinicians' experiences with treatment decision making for older persons with multiple conditions. Arch Intern Med 2011; 171:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/36\">",
"      Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004; 351:2870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/37\">",
"      Safford MM, Allison JJ, Kiefe CI. Patient complexity: more than comorbidity. the vector model of complexity. J Gen Intern Med 2007; 22 Suppl 3:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/38\">",
"      Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51:S265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/39\">",
"      Morris RL, Sanders C, Kennedy AP, Rogers A. Shifting priorities in multimorbidity: a longitudinal qualitative study of patient's prioritization of multiple conditions. Chronic Illn 2011; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/40\">",
"      Whitson HE, Steinhauser K, Ammarell N, et al. Categorizing the effect of comorbidity: a qualitative study of individuals' experiences in a low-vision rehabilitation program. J Am Geriatr Soc 2011; 59:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/41\">",
"      Yarnall KS, Pollak KI, &Oslash;stbye T, et al. Primary care: is there enough time for prevention? Am J Public Health 2003; 93:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/42\">",
"      &Oslash;stbye T, Yarnall KS, Krause KM, et al. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med 2005; 3:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/43\">",
"      Hou JK, Abudayyeh S, Shaib Y. Treatment of chronic radiation proctitis with cryoablation. Gastrointest Endosc 2011; 73:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/44\">",
"      Fick DM, Waller JL, Maclean JR, et al. Potentially inappropriate medication use: Prevalence and association with resource utilization in an elderly managed care population. J Managed Care Pharm 2001; 7:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/45\">",
"      Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/46\">",
"      Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006; 5:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/47\">",
"      Knottnerus JA, Dinant GJ. Medicine based evidence, a prerequisite for evidence based medicine. BMJ 1997; 315:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/48\">",
"      Hardy SE, Allore H, Studenski SA. Missing data: a special challenge in aging research. J Am Geriatr Soc 2009; 57:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/49\">",
"      Fortin M, Dionne J, Pinho G, et al. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med 2006; 4:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/50\">",
"      Lash TL, Mor V, Wieland D, et al. Methodology, design, and analytic techniques to address measurement of comorbid disease. J Gerontol A Biol Sci Med Sci 2007; 62:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/51\">",
"      Satariano WA, Silliman RA. Comorbidity: implications for research and practice in geriatric oncology. Crit Rev Oncol Hematol 2003; 48:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/52\">",
"      Smith SM, Soubhi H, Fortin M, et al. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev 2012; 4:CD006560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/53\">",
"      Berwick DM. A user's manual for the IOM's 'Quality Chasm' report. Health Aff (Millwood) 2002; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/54\">",
"      Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract 2000; 49:796.",
"     </a>",
"    </li>",
"    <li>",
"     Campaign for Better Care. Available at: file://www.nationalpartnership.org/site/PageServer?pagename=cbc_intro_landing (Accessed on October 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/56\">",
"      Belcher VN, Fried TR, Agostini JV, Tinetti ME. Views of older adults on patient participation in medication-related decision making. J Gen Intern Med 2006; 21:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/57\">",
"      Reuben DB. Better ways to care for older persons: is anybody listening? J Am Geriatr Soc 2009; 57:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/58\">",
"      Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention: results of a randomized controlled trial. Arch Intern Med 2006; 166:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/59\">",
"      Boockvar K, Fishman E, Kyriacou CK, et al. Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. Arch Intern Med 2004; 164:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/60\">",
"      Moore C, Wisnivesky J, Williams S, McGinn T. Medical errors related to discontinuity of care from an inpatient to an outpatient setting. J Gen Intern Med 2003; 18:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/61\">",
"      Coleman EA. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. J Am Geriatr Soc 2003; 51:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/62\">",
"      Harrison A, Verhoef M. Understanding coordination of care from the consumer's perspective in a regional health system. Health Serv Res 2002; 37:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/63\">",
"      Chaudhry B, Wang J, Wu S, et al. Systematic review: impact of health information technology on quality, efficiency, and costs of medical care. Ann Intern Med 2006; 144:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/64\">",
"      Blumenthal D, Glaser JP. Information technology comes to medicine. N Engl J Med 2007; 356:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/65\">",
"      McAllister JW, Presler E, Cooley WC. Practice-based care coordination: a medical home essential. Pediatrics 2007; 120:e723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/66\">",
"      Boult C, Rassen J, Rassen A, et al. The effect of case management on the costs of health care for enrollees in Medicare Plus Choice plans: a randomized trial. J Am Geriatr Soc 2000; 48:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/67\">",
"      Wolff JL, Roter DL. Hidden in plain sight: medical visit companions as a resource for vulnerable older adults. Arch Intern Med 2008; 168:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/68\">",
"      Soubhi H, Fortin M, Hudon C. Perceived conflict in the couple and chronic illness management: preliminary analyses from the Quebec Health Survey. BMC Fam Pract 2006; 7:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/69\">",
"      Rosland AM, Heisler M, Choi HJ, et al. Family influences on self-management among functionally independent adults with diabetes or heart failure: do family members hinder as much as they help? Chronic Illn 2010; 6:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/70\">",
"      Mitnick S, Leffler C, Hood VL, American College of Physicians Ethics, Professionalism and Human Rights Committee. Family caregivers, patients and physicians: ethical guidance to optimize relationships. J Gen Intern Med 2010; 25:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/71\">",
"      Wolff JL, Roter DL, Given B, Gitlin LN. Optimizing patient and family involvement in geriatric home care. J Healthc Qual 2009; 31:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/72\">",
"      Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract 1998; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/73\">",
"      Boult C, Wieland GD. Comprehensive primary care for older patients with multiple chronic conditions: \"Nobody rushes you through\". JAMA 2010; 304:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/74\">",
"      Boyd CM, Boult C, Shadmi E, et al. Guided care for multimorbid older adults. Gerontologist 2007; 47:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/75\">",
"      Boyd CM, Reider L, Frey K, et al. The effects of guided care on the perceived quality of health care for multi-morbid older persons: 18-month outcomes from a cluster-randomized controlled trial. J Gen Intern Med 2010; 25:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/76\">",
"      Boult C, Reider L, Leff B, et al. The effect of guided care teams on the use of health services: results from a cluster-randomized controlled trial. Arch Intern Med 2011; 171:460.",
"     </a>",
"    </li>",
"    <li>",
"     Weiland D. The Program of All-Inclusive Care for the Elderly PACE. In: The Encyclopedia of Aging, 4th Ed., Schultz R, Neolker L, Rockwood K, Sprott R (Eds), Springer, New York 2006. p.973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/78\">",
"      Counsell SR, Callahan CM, Buttar AB, et al. Geriatric Resources for Assessment and Care of Elders (GRACE): a new model of primary care for low-income seniors. J Am Geriatr Soc 2006; 54:1136.",
"     </a>",
"    </li>",
"    <li>",
"     The Patient Centered Medical Home: History, Seven Core Features, Evidence, and Transformational Change. Available at: file://www.graham-center.org/PreBuilt/PCMH.pdf (Accessed on October 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/80\">",
"      Von Korff M, Katon WJ, Lin EH, et al. Functional outcomes of multi-condition collaborative care and successful ageing: results of randomised trial. BMJ 2011; 343:d6612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/81\">",
"      Tinetti ME. Making prevention recommendations relevant for an aging population. Ann Intern Med 2010; 153:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/82\">",
"      Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/83\">",
"      Walter LC, Lewis CL, Barton MB. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med 2005; 118:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/84\">",
"      Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 2006; 56:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/85\">",
"      Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006; 295:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/86\">",
"      Wolf MS, Shekelle P, Choudhry NK, et al. Variability in pharmacy interpretations of physician prescriptions. Med Care 2009; 47:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11417/abstract/87\">",
"      Giovannetti ER, Wolff JL, Xue QL, et al. Difficulty assisting with health care tasks among caregivers of multimorbid older adults. J Gen Intern Med 2012; 27:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16526 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11417=[""].join("\n");
var outline_f11_9_11417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30020203\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30994423\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30629397\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30629384\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30994430\">",
"      IMPACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30994437\">",
"      PATIENT CARE CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30994444\">",
"      Adherence to multiple clinical practice guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30994451\">",
"      Competing demands and shifting priorities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30994459\">",
"      Polypharmancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30994466\">",
"      Limited evidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30994473\">",
"      APPROACH TO THE PATIENT WITH MULTIMORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30994480\">",
"      Elicit patient goals and priorities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30994487\">",
"      Coordination of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30994494\">",
"      Less may be best",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30994501\">",
"      Identify and address issues that impact multiple conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624058\">",
"      Common disease-specific considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H624113\">",
"      - Diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H624140\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30020203\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16526\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16526|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/38/23151\" title=\"algorithm 1\">",
"      Older adult multimorbidity eval and mgmt algo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16526|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/32/23053\" title=\"table 1\">",
"      Tx guidelines comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/8/43148\" title=\"table 2\">",
"      Clinical practice recs for multiple comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/38/24172\" title=\"table 3\">",
"      Tips for specific patient impairments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=related_link\">",
"      Comprehensive geriatric assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12330?source=related_link\">",
"      Hospital discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/34/32290?source=related_link\">",
"      Patient information: Taking medicines when you're older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/18/11554?source=related_link\">",
"      Patient information: When you have depression and another health problem (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/36/27202?source=related_link\">",
"      Patient information: When you have multiple health problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=related_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_9_11418="Clinical presentation and evaluation of chronic kidney disease in children";
var content_f11_9_11418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and evaluation of chronic kidney disease in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11418/contributors\">",
"     Craig S Wong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11418/contributors\">",
"     Bradley A Warady, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11418/contributors\">",
"     Tarak Srivastava, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11418/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11418/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/9/11418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/9/11418/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/9/11418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease (CKD) refers to a state of irreversible kidney damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction of kidney function that can lead to a progressive decrease in kidney function. It is now the accepted term in the pediatric nephrology community, replacing the clinical terms of chronic renal failure (CRF) and chronic renal insufficiency (CRI), which describe renal dysfunction of varying degrees from severe to mild in nature. CKD more clearly defines renal dysfunction as a continuum, rather than a discrete change in renal function and will be used throughout this topic review.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and evaluation of CKD in children will be reviewed here. The etiology, epidemiology, natural course, and management of CKD in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    has defined CKD as a disorder lasting three or more months with either kidney damage defined by structural or functional abnormalities of the kidney with or without decreased estimated glomerular filtration rate (GFR), or a GFR of less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    workgroup also developed a classification schema for patients with CKD who are older than two years of age based upon the level of kidney function as follows (",
"    <a class=\"graphic graphic_table graphicRef80596 \" href=\"UTD.htm?22/4/22603\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 disease &mdash; Normal GFR (&ge;90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2)",
"     </li>",
"     <li>",
"      Stage 2 disease &mdash; GFR between 60 and 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 3 disease &mdash; GFR between 30 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 4 disease &mdash; GFR between 15 and 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 5 disease &mdash; GFR of less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 or end-stage renal disease (ESRD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal levels of GFR vary with age, gender, and body size. GFR increases with maturation from infancy, and approaches an adult mean value by two years of age (",
"    <a class=\"graphic graphic_table graphicRef55965 \" href=\"UTD.htm?19/61/20443\">",
"     table 2",
"    </a>",
"    ). Children under two years of age do not fit within the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    classification system because they normally have a low GFR even when corrected for body surface area. In these patients, calculated GFR based upon serum creatinine can be compared to normative age-appropriate values to detect renal impairment. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Laboratory testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The classification schema is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Definitions and classifications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of CKD is dependent upon the severity of renal impairment and the underlying disorder. Patients presenting during the early stages of CKD (eg, stages 1 and 2) are typically asymptomatic. As CKD progresses and kidney function deteriorates, patients become increasingly symptomatic.",
"   </p>",
"   <p>",
"    Given the heterogeneity of causes for pediatric chronic kidney injury, signs and symptoms vary and include different amounts of urine output (polyuria, oliguria, or anuria), edema, hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discolored urine. Patients with glomerular disease may present with hematuria, proteinuria, hypertension, and edema in the early stages of CKD, which may persist into later stages.",
"   </p>",
"   <p>",
"    Patients with kidney disease may present in a variety of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyuria may be an early presenting finding because many congenital anomalies of the kidney and urinary tract (eg, obstructive uropathy), inherited disorders (eg, nephronophthisis), and tubulointerstitial disorders are associated with reduced concentrating ability (ie, nephrogenic diabetes insipidus). In these conditions, the impairment in renal concentration capacity generally precedes a significant reduction in GFR.",
"     </li>",
"     <li>",
"      Elevation in the serum creatinine concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormalities on urinalysis may be an incidental finding during evaluation for another condition.",
"     </li>",
"     <li>",
"      Proteinuria is a strongly-associated biomarker of CKD and is a possible sign of underlying glomerular disease or tubular dysfunction. Persistent (&ge;3 months) increased excretion of urinary protein in a non-orthostatic pattern is indicative of CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link\">",
"       \"Evaluation of proteinuria in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detection of congenital or structural anomalies by imaging studies, particularly prenatal ultrasonography. Approximately 60 percent of childhood cases of CKD are due to congenital anomalies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poor growth is a common manifestation of CKD in children. This was best illustrated by the 2008 annual report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/2\">",
"       2",
"      </a>",
"      ]. Of the 7037 patients with baseline height measurements registered into the chronic renal insufficiency database from 1994 to 2008, the mean height and weight were 1.44 and 0.88 standard deviations below age- and gender-specific normal values, respectively. These patients had a mean serum creatinine of 2.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (range 1.5 to 3.0",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      with a mean estimated GFR by the Schwartz formula of 39",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m2. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Growth impairment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of severe renal impairment or renal failure begin to appear in some patients with stage 3 disease and are present in those with stages 4 and 5 disease. These symptoms (referred to as symptoms of uremia) include anorexia, vomiting, weakness and easy fatigability. Other findings attributable to the uremic state include pericarditis, deficits in neurocognitive function, and osteodystrophy.",
"     </li>",
"     <li>",
"      Systemic symptoms and findings due to a concurrent systemic disease that affects renal function resulting in CKD, such as lupus nephritis or Wegener's granulomatosis. Clinical manifestations may include fever,",
"      <span class=\"nowrap\">",
"       arthralgias/arthritis,",
"      </span>",
"      rash, or pulmonary symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A moderate to severe loss of GFR (ie, stage 3 to 5 disease), (",
"    <a class=\"graphic graphic_table graphicRef80596 \" href=\"UTD.htm?22/4/22603\">",
"     table 1",
"    </a>",
"    ) is associated with a number of complications due to impairment of the many functions performed by the kidney. These complications may be the presenting sign or symptom of CKD and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disorders of fluid and electrolytes",
"     </li>",
"     <li>",
"      Disorders of mineral metabolism and renal osteodystrophy",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Endocrine abnormalities",
"     </li>",
"     <li>",
"      Growth impairment",
"     </li>",
"     <li>",
"      Decreased clearance of renally excreted substances from the body (uremia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single center retrospective study reviewed the prevalence rate of associated complications in 366 children with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/3\">",
"     3",
"    </a>",
"    ]. In this cohort, 57 percent of patients had stage 1, 29 percent stage 2, 10 percent stage 3, and 4 percent had either stage 4 or 5 disease.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension &mdash; 70 percent",
"     </li>",
"     <li>",
"      Anemia &mdash; 37 percent",
"     </li>",
"     <li>",
"      CKD-mineral and bone disorder (CKD-MBD) &mdash; 17 percent",
"     </li>",
"     <li>",
"      Growth failure &mdash; 12 percent",
"     </li>",
"     <li>",
"      Electrolyte disorder or metabolic acidosis requiring intervention &mdash; 12 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2011, the multicenter prospective Chronic Kidney Disease in Children (CKiD) study reported the prevalence rate of the following complications based on data from 586 participants with moderate to severe CKD (median GFR = 43",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia (hemoglobin &lt;5",
"      <sup>",
"       th",
"      </sup>",
"      percentile or the use of erythropoietin) &mdash; 38 percent",
"     </li>",
"     <li>",
"      Growth failure (height &lt;3",
"      <sup>",
"       rd",
"      </sup>",
"      percentile) &mdash; 16 percent",
"     </li>",
"     <li>",
"      Uncontrolled systolic hypertension &mdash; 14 percent",
"     </li>",
"     <li>",
"      Uncontrolled diastolic hypertension &mdash; 13 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology of these abnormalities will be discussed in this section, and the work-up to detect these abnormalities is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Evaluation at presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The management of these complications is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fluid and electrolyte abnormalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sodium and water balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidneys normally can adapt to a wide range of sodium and water intake. Sodium and intravascular volume balance are usually maintained via homeostatic mechanisms until the GFR falls below 10 to 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. However, the patient with mild to moderate CKD, despite being in relative volume balance, is less able to respond to rapid infusions of sodium and is, therefore, prone to fluid overload.",
"   </p>",
"   <p>",
"    As the kidney function becomes severely impaired (ie, stages 4 and 5 disease), water retention may result in volume overload. In some cases, especially with an acute water load, hyponatremia and hypertension may occur as a consequence of fluid retention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H13#H13\">",
"     \"Causes of hyponatremia\", section on 'Advanced renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients, such as those with nephronophthisis and some with obstructive uropathy, have an impaired ability to concentrate urine, and have symptoms of polyuria. These children are at risk for hypovolemia, as they will continue to have large urine losses even when they are volume depleted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with CKD, hyperkalemia develops primarily because of inadequate potassium excretion due to reduced GFR. Also, potassium excretion is dependent upon an exchange with sodium at the distal tubule. A low GFR results in decreased delivery of sodium to this site, resulting in a reduced exchange rate with potassium and inadequate potassium excretion.",
"   </p>",
"   <p>",
"    Other contributory factors for hyperkalemia include",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High dietary potassium intake",
"     </li>",
"     <li>",
"      Catabolic conditions with increased tissue breakdown",
"     </li>",
"     <li>",
"      Metabolic acidosis",
"     </li>",
"     <li>",
"      Secondary type IV RTA in some patients with obstructive uropathy",
"     </li>",
"     <li>",
"      Decreased renin production by the juxtaglomerular apparatus",
"     </li>",
"     <li>",
"      Primary or secondary hypoaldosteronism (eg, administration of an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, calcineurin inhibitors,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prostaglandin inhibitors)",
"     </li>",
"     <li>",
"      Impaired cellular uptake of potassium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic acidosis is a common complication of advanced renal disease. Total ammonium excretion begins to fall when the GFR decreases to below 40 to 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 (stage 3 disease). At this time, ammonium excretion is three to four times above normal per nephron so that the impairment in ammonium excretion is due to too few functioning nephrons rather than impaired function in the remaining nephrons. In addition, there is a reduction in both titratable acid excretion (primarily as phosphate) and bicarbonate reabsorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect is retention of hydrogen ions resulting in metabolic acidosis. In children, overt acidosis is characteristically present in stage 4 disease with a GFR below 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. The anion gap is usually increased in this setting, but may be normal due to the concomitant retention of anions such as phosphate, sulfate, urate, and hippurate.",
"   </p>",
"   <p>",
"    As the patient approaches ESRD, the serum bicarbonate concentration tends to stabilize between 12 and 20",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    A level below 10",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    is unusual, as buffering of the retained hydrogen ions by various body buffers prevents a progressive fall in the bicarbonate concentration",
"   </p>",
"   <p>",
"    In children with CKD, the presence of acidosis has a negative impact on growth, as the body utilizes bone to buffer the excess hydrogen ions. This is illustrated in children with renal tubular acidosis in whom there is a return of normal growth following normalization of the serum bicarbonate level. In children with CKD, the treatment of osteodystrophy is more effective if the acidosis is corrected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3526557\">",
"    <span class=\"h2\">",
"     CKD-MBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease-mineral and bone disorder (CKD-MBD) presents as a broad clinical spectrum encompassing abnormalities in mineral metabolism, bone structure, and extraskeletal calcifications that are found with progressive CKD. The National Kidney Foundation recommends the term renal osteodystrophy be used exclusively to define the changes in bone morphology associated with CKD.",
"   </p>",
"   <p>",
"    CKD-MBD, when untreated, can first be detected in children with stage 2 CKD disease. Although these patients have no signs or symptoms related to bone disease, they may have a reduced serum calcidiol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcitriol levels, and an elevated serum PTH and FGF-23 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Patients with more advanced CKD-MBD have bone pain, difficulty in walking,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skeletal deformities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    CKD-MBD in children with CKD is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link\">",
"     \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of CKD is due to reduced renal erythropoietin production. Although the exact level of GFR at which anemia develops is not well defined, one study of children with CKD reported that anemia began to develop at a measured GFR threshold of 43",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/11\">",
"     11",
"    </a>",
"    ]. The measured value equated with an estimated Schwartz GFR of 58",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73 m2.",
"   </p>",
"   <p>",
"    The anemia of CKD is principally normocytic and normochromic. By comparison, the finding of microcytosis may reflect iron deficiency or aluminum excess, while macrocytosis may be associated with vitamin B12 or folate deficiency. These causes of anemia also occur more frequently in children with CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If left untreated, the anemia of CKD is associated with fatigue, weakness, decreased attentiveness, increased somnolence, and poor exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/7,12-14\">",
"     7,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk for cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with CKD are at risk for developing early atherosclerosis and premature cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/15\">",
"     15",
"    </a>",
"    ]. Cardiovascular disease is the leading cause of death in children and young adults with CKD. Young adults (25 to 34 years) with CKD have at least a 100-fold higher risk for CVD related mortality compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/16\">",
"     16",
"    </a>",
"    ]. As a result, CKD is one of the chronic diseases associated with an increased risk for coronary artery disease (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link&amp;anchor=H5#H5\">",
"     \"Diseases associated with atherosclerosis in childhood\", section on 'Chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase incidence of premature CVD is due to the high prevalence of CVD risk factors in children with CKD. A study from the Chronic Kidney Disease in Children (CKiD) cohort reported 39, 22, and 13 percent of patients had 1, 2, or &ge; 3 CVD risk factors, respectively, at their first annual follow-up visit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/17\">",
"     17",
"    </a>",
"    ]. CVD risk factors and their relative frequency included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension (HTN, defined as blood pressure &gt;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile or self-reported HTN with concurrent use of antihypertensive agents) &ndash; 46 percent",
"     </li>",
"     <li>",
"      Dyslipidemia &ndash; 44 percent",
"     </li>",
"     <li>",
"      Abnormal glucose metabolism (defined as fasting glucose &gt;110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.6",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      insulin &gt;20",
"      <span class=\"nowrap\">",
"       microIU/mL",
"      </span>",
"      or elevated homeostasis model assessment of insulin resistance based on Tanner stages) &ndash; 21 percent",
"     </li>",
"     <li>",
"      Obesity (body mass index &gt;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile) &ndash; 15 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this same study, multivariable analysis demonstrated that children with a glomerular etiology of CKD and proteinuria were more likely to have CVD risk factors. Children with non-glomerular CKD and proteinuria (defined as a urine protein to creatinine ratio &gt;2) had an approximate threefold increase of having more CVD risk factors compared with those with lower levels of proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of hypertension is high in children with CKD, ranging from 54 to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/3,18\">",
"     3,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertension is due to volume expansion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activation of the renin-angiotensin system. In some cases, hypertension may be due in part to medications (eg, corticosteroids or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) that are used to treat the underlying renal disease.",
"   </p>",
"   <p>",
"    Unlike many of the complications of CKD, hypertension can be present in the earliest stages of CKD, and its prevalence increases with progressive declines in GFR. This was shown in a study of 366 children with CKD from a single center that demonstrated the prevalence of hypertension increased from 63 percent of patients with stage 1 to 80 percent of those with stage 4 and 5 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy (LVH) is a common finding in patients with CKD, and occurs as a response to mechanical or hemodynamic overload [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/15\">",
"     15",
"    </a>",
"    ]. There are two different patterns of LVH: concentric LVH, which occurs in the presence of hypertension, and eccentric LVH, which is associated with volume overload and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another report of 366 children with CKD stages 2 through 4 from the multicenter CKiD study, 17 percent of patients had LVH detected by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/20\">",
"     20",
"    </a>",
"    ]. Eccentric LVH was seen in 11 percent and concentric in the remaining 6 percent. Nine percent also had concentric remodeling of the left ventricle. BP evaluation, including ambulatory and office measurements, demonstrated confirmed HTN (both elevated ambulatory and office BPs) in 18 percent and masked HTN (normal office but elevated ambulatory BP) in 38 percent of patients. LVH was more common in children with confirmed and masked HTN compared to those with normal BP measurements (34, 20 and 8 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174930617\">",
"    <span class=\"h3\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal lipid metabolism is common in patients with CKD and as noted above, is one of the primary factors that increase the risk for cardiovascular disease (CVD).",
"   </p>",
"   <p>",
"    As an example, a report of 391 children from the CKiD study identified a lipid abnormality in 45 percent of the cohort, and more than one abnormal value in 20 percent of the group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/21\">",
"     21",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      32 percent had hypertriglyceridemia &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      21 percent had elevated low high-density lipoprotein cholesterol (HDL-C, &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      16 percent had elevation of non-HDL-C (&gt;160",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      A GFR of &lt;30",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      was associated with an increased odds ratio for any dyslipidemia and combined (more than one abnormality) dyslipidemia.",
"     </li>",
"     <li>",
"      Compared with those of normal weight, overweight (BMI percentile 85 to 95) and obese (BMI percentile &gt;95) individuals were five to seven times more likely to have combined dyslipidemia independent of their level of GFR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because dyslipidemia is a common finding in children with CKD, the American Academy of Pediatrics, American Heart Association and an expert panel sponsored by the United States National Heart, Lung, Blood Institute recommend that all children with one or more known atherosclerotic risks or condition associated with CVD (including CKD) be screened for dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/281?source=see_link\">",
"     \"Definition and screening for dyslipidemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link\">",
"     \"Management of pediatric dyslipidemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6248?source=see_link\">",
"     \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endocrine dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CKD, the following endocrine systems become dysfunctional as kidney function progressively deteriorates. Each of these is discussed in greater detail separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth hormone metabolism &mdash; CKD is associated with a variety of abnormalities in growth hormone (GH) metabolism including changes in the plasma concentration of GH, its release, and its end-organ responsiveness. In particular, end-organ resistance to GH due to increased levels of insulin growth factor binding proteins appears to play a major role in growth impairment in children with CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Growth impairment'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17509?source=see_link\">",
"       \"Growth hormone metabolism in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyroid function &mdash; In patients with CKD, alterations in the production, distribution, and excretion of thyroid hormones occur with increasing renal dysfunction. These abnormalities are generally characterized by low total and free T4 and T3, a normal thyroid stimulating hormone (TSH) level, and normal or decreased thyroid hormone-binding globulin levels or thyrotropin-releasing hormone (TRH) stimulation test results. These findings are consistent with the \"Sick euthyroid syndrome\" seen in other chronic diseases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2453?source=see_link\">",
"       \"Thyroid function in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gonadal hormones &mdash; There are abnormalities in gonadal hormones in both male and female patients, which result in delayed puberty in two-thirds of adolescents with ESRD [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/23\">",
"       23",
"      </a>",
"      ]. The average pubertal delay in children with CKD is 2.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In males, abnormalities include reduced levels of serum free testosterone, dihydrotestosterone, and adrenal androgens, and increases in serum lutenizing hormone (LH) and follicle stimulating hormone (FSH). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20951?source=see_link\">",
"       \"Sexual dysfunction in uremic men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postpubertal females with CKD have reduced serum estrogen, elevated LH and FSH, and loss of the LH pulsatile pattern. These disturbances result in anovulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36484?source=see_link\">",
"       \"Reproductive and sexual dysfunction in uremic women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Growth impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of growth failure, a common complication of childhood CKD, is multifactorial and includes metabolic acidosis, decreased caloric intake, CKD-MBD, renal osteodystrophy, and alterations in the function of the growth hormone and insulin-like growth factor (IGF-1) axis. In particular, poor linear growth is primarily due to increased levels of insulin growth factor binding proteins, which promotes a growth hormone resistant state resulting in short stature [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17509?source=see_link\">",
"     \"Growth hormone metabolism in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Birth factors may also affect growth in children with CKD. In an observational study of 426 patients with mild to moderate CKD from the CKiD cohort, multivariate analysis demonstrated that low birth weight (defined as &lt;2500 g ) and small for gestational age (SGA)(defined as a birth weight &lt;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile for gestational age) were negative independent factors on current height and weight [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Uremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of ESRD (ie, stage 5 CKD) results in a constellation of signs and symptoms referred to as uremia. Manifestations of the uremic state include anorexia, nausea, vomiting, growth retardation, peripheral neuropathy, and central nervous system abnormalities ranging from loss of concentration and lethargy to seizures, coma, and death.",
"   </p>",
"   <p>",
"    Symptoms attributed to uremia are present before the development of severe renal impairment. In the CKiD cohort, subjects exhibited physical symptoms of decreased alertness, loss of appetite, weakness, and leg pain in association with mild to moderate CKD. The prevalence of these symptoms increased with decreasing level of GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other complications of uremia include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet dysfunction &mdash; Patients who are uremic also have an increased tendency to bleed secondary to abnormal platelet adhesion and aggregation properties. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"       \"Platelet dysfunction in uremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pericardial disease &mdash; Pericardial disease (pericarditis and pericardial effusion) is an indication to institute dialysis in children with CKD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Uremic pericarditis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6533?source=see_link\">",
"       \"Pericarditis in renal failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Kidney function that is less than 5 percent of normal is believed to be insufficient to sustain life and requires renal replacement therapy (RRT). The initiation of RRT should be considered when the GFR falls below 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2. The indications for RRT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Renal replacement therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"     \"Indications for initiation of dialysis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Neurodevelopment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremia is associated with alterations of cognitive development in children. The neurologic findings can range from seizures and severe intellectual disability (mental retardation) to subtle deficits resulting in poor school performance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, the neurodevelopmental outcomes of infants and small children with CKD were dismal, in large part as a result of malnutrition and aluminum exposure. Subsequently, with improvement in nutritional management, avoidance of aluminum, and optimization of dialysis and anemia management, the neurodevelopmental outcome has been more encouraging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 34 infants who started dialysis at less than three months of age showed that 79 percent had a normal mental development score at one year follow-up, and only 4 percent were significantly delayed. At greater than four years of age, 79 percent performed in the average range, while 5 percent were impaired; at greater than five years of age, 94 percent attended full-time school in age-appropriate classrooms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 33 children transplanted at less than five years of age showed that 79 percent attended normal school and 76 percent had normal motor performance. The mean intelligence quotient was 87, and only 6 to 24 percent showed impairment on special neuropsychological tests [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a CKiD study of 368 children between ages 6 and 16 years with a median measured GFR of 43",
"      <span class=\"nowrap\">",
"       mL/min/",
"      </span>",
"      1,73 m",
"      <sup>",
"       2",
"      </sup>",
"      and eight years median duration of CKD, the neurocognitive function was within the normal range for the entire cohort [",
"      <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/28\">",
"       28",
"      </a>",
"      ]. &nbsp;In addition, the overall attention and parental rating of executive function were age-appropriate. However, a large portion of the children in this cohort were found to be at-risk for neurocognitive dysfunction, defined as test performance &ge; 1 SD below the normative mean. This was especially noteworthy for parent ratings of executive functioning, where 27 to 40 percent of children were characterized as being at-risk for further delay.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the neurocognitive outcomes are more optimistic compared to the past, the longitudinal data on this subject are limited. It appears that children do remain at risk for neurocognitive dysfunction and require close monitoring with CKD progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Quality of life'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sleep and fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daytime sleepiness and fatigue are commonly seen in children with CKD and increase with decreasing kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This was illustrated in a report of 301 children with stages 2 through 4 CKD from the CKiD study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe weakness was more frequent in children with a GFR below 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 compared with children with a GFR at or greater than 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2.",
"     </li>",
"     <li>",
"      Children with a GFR below 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 were more likely to fall asleep during the day compared with those with a GFR at or greater than 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2.",
"     </li>",
"     <li>",
"      Low energy, trouble sleeping, and weakness were associated with a lower health related quality of life score. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H31#H31\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Quality of life'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sleep disorders (restless leg",
"    <span class=\"nowrap\">",
"     syndrome/paroxysmal",
"    </span>",
"    leg movements, sleep-disordered breathing, excessive daytime sleepiness, and insomnia) are also common in children with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=see_link\">",
"     \"Assessment of sleep disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     EVALUATION AT PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a child with CKD begins with a history and physical examination. Imaging and laboratory evaluation are useful to determine the underlying cause of CKD. Laboratory testing is also critical to determine the severity of renal impairment and whether any associated complications of CKD are present. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Complications of CKD'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include documentation of the age at onset of symptoms, duration of symptoms, type of symptoms due to uremia (weakness, fatigue, anorexia, or vomiting), systemic diseases (fever, rash, or",
"    <span class=\"nowrap\">",
"     arthralgias/arthritis),",
"    </span>",
"    or specific renal disorders (eg, glomerulonephritis with hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    edema). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The history is focused on signs of CKD or factors that increase the risk of CKD, the list of which should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of renal disease or hypertension",
"     </li>",
"     <li>",
"      Growth history, particularly poor linear growth",
"     </li>",
"     <li>",
"      Polyuria, polydipsia, or enuresis",
"     </li>",
"     <li>",
"      Elevated blood pressure",
"     </li>",
"     <li>",
"      Antenatal diagnosed congenital anomaly of the kidney or urinary tract (CAKUT)",
"     </li>",
"     <li>",
"      Orthopedic or urologic abnormalities",
"     </li>",
"     <li>",
"      Recurrent urinary tract infection",
"     </li>",
"     <li>",
"      Unexplained anemia",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Fluid and electrolyte disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relevance of these factors is supported by 2008 data from the CRI registry of the NAPRTCS that shows the following medical events experienced by patients with CKD (n=7037) and their associated frequencies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluid and electrolyte abnormality &mdash; 44 percent",
"     </li>",
"     <li>",
"      Urologic surgery &mdash; 33 percent",
"     </li>",
"     <li>",
"      Urinary tract infection &mdash; 34 percent",
"     </li>",
"     <li>",
"      Renal biopsy &mdash; 23 percent",
"     </li>",
"     <li>",
"      Blood transfusions &mdash; 11 percent",
"     </li>",
"     <li>",
"      Seizures &mdash; 8 percent",
"     </li>",
"     <li>",
"      Radiologic examination of the hip &mdash; 7 percent",
"     </li>",
"     <li>",
"      Orthopedic surgery &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of any child suspected of having CKD should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of growth parameters (height, weight, and, for patients &le; 3 years of age, head circumference), as these children are at risk for poor growth.",
"     </li>",
"     <li>",
"      Blood pressure measurement, as hypertension often occurs in children with CKD due to underlying renal pathology, hypervolemia due to impaired water excretion, or certain medications. Blood pressure values are compared to normative BP percentiles based upon gender, age, and height from the National Health and Nutrition Examination Survey (NHANES) and other population-based studies (",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"       table 4",
"      </a>",
"      ). The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pallor as an indication of anemia should be assessed for by examining sites where capillary beds are visible through the mucosa (eg, conjunctiva, palm, and nail beds).",
"     </li>",
"     <li>",
"      Examination of the extremities for any deformity as an indication of CKD-MBD or edema as an indication of nephrotic syndrome. The site and type of deformity of the extremities depend upon the age of the child and the weight-bearing patterns in the limbs, and are similar to those found in children with rickets. Thus, deformities of the forearms and posterior bowing of the distal tibia are found more commonly in the infant, whereas an exaggeration of the normal physiological bowing of the legs (genu varum) is a characteristic finding in the toddler who has started to walk. In the older child, valgus deformities of the legs or a windswept deformity (valgus deformity of one leg and varus deformity of the other) may be apparent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link\">",
"       \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"       \"Overview of rickets in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment for any sign of hypervolemia by noting the",
"      <span class=\"nowrap\">",
"       presence/absence",
"      </span>",
"      of edema, rales, hepatic",
"      <span class=\"nowrap\">",
"       enlargement/tenderness,",
"      </span>",
"      or cardiac gallop.",
"     </li>",
"     <li>",
"      Cardiac auscultation to detect a pericardial rub due to pericarditis or diminished heart sounds secondary to a pericardial effusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging may be useful in identifying the underlying cause of CKD and assessing a decrease in renal parenchyma.",
"   </p>",
"   <p>",
"    Ultrasonography (US) is the most widely used modality and is a noninvasive procedure. It assesses the growth and the structure of the kidneys. The ultrasound examination should compare the measured length of each kidney to normative age-appropriate values (",
"    <a class=\"graphic graphic_figure graphicRef79848 \" href=\"UTD.htm?32/49/33566\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Renal length measurement is generally performed in the sagittal plane with the patient in a supine position or contralateral decubitus position [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. Kidneys that are smaller than normal indicate a decrease in renal mass due to congenital maldevelopment (eg, renal hypoplasia), poor growth, or loss of nephrons due to an underlying disorder or injury.",
"   </p>",
"   <p>",
"    In children with a solitary kidney with CKD, renal length is generally in the upper range of length for normal paired kidneys and often is greater than the 95 percentile due to compensatory renal hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, the normative values based upon age may result in over-reporting of small kidneys based on age in children with CKD who are growth retarded, because kidney size is related to the child's height. In these patients, normative values based upon the child's height can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/33\">",
"     33",
"    </a>",
"    ]. Ultrasonography may also be diagnostic for underlying causes of CKD, such as detecting cystic kidney disease.",
"   </p>",
"   <p>",
"    Other imaging studies include voiding cystourethrogram (VCUG), computed tomography (CT), and magnetic resonance imaging (MRI), which are used in specific clinical settings, or when better resolution or visualization is required than that provided by ultrasonography. For example, VCUG would be used to detect vesicoureteral reflux in a patient with hydronephrosis or recurrent urinary tract infection.",
"   </p>",
"   <p>",
"    Ionic and nonionic contrast agents used for radiographic procedures and imaging studies may be nephrotoxic and cause acute renal dysfunction. Gadolinium-based contrast agents for MRI and MR angiography have been associated with nephrogenic fibrosing dermopathy and sometimes fatal nephrogenic systemic fibrosis (NSF) in both children and adults with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Thus, contrast agents should be used with caution in patients with CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H4#H4\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'Gadolinium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the type of kidney disease, blood and urine studies are often used to support the diagnosis of CKD. Abnormalities in these assessments may not be readily apparent during the early stages of CKD, but will become increasingly prevalent as the GFR decreases. Whereas there is no single pattern of laboratory abnormalities that characterize pediatric CKD, there are some abnormalities that are commonly present and are indicative of underlying chronic kidney dysfunction. In addition, serum creatinine is obtained as an estimate of GFR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Serum creatinine and GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum creatinine is the most commonly used test to estimate the GFR. Developed in the 1970s, the Schwartz formula has been the method used most often to estimate GFR in children and adolescents.",
"   </p>",
"   <p>",
"    The original formula was based upon serum creatinine determined by the Jaffe method, height, and an aged based constant k that varied with age (and in adolescents the gender of the patient) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?23/40/24193?source=see_link\">",
"     calculator 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    GFR = k X Height (cm)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    Screat (Jaffe method)",
"   </p>",
"   <p>",
"    Height represents the body height measured in centimeters, and Screat is the serum creatinine value in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    as determined by the Jaffe method. The constant k is directly proportional to the muscle component of body, and varies with age. The value for k is 0.33 in premature infants through the first year of life, 0.45 for term infants through the first year of life, 0.55 in children and adolescent girls, and 0.7 in adolescent boys.",
"   </p>",
"   <p>",
"    However, because the now commonly used enzymatic method for creatinine determination results in a lower value of creatinine compared to the older Jaffe method, the Schwartz formula generally overestimates GFR compared to measured values [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. One of the goals of the Chronic Kidney Disease in Children (CKiD) study has been to find a way to more accurately estimate GFR than the Schwartz formula from easily obtainable blood tests in children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A bedside formula based upon serum creatinine measured by the enzymatic method and derived from data collected from 349 children enrolled in CKiD appears to be promising as a more accurate estimation of GFR in children with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    GFR = 0.413 X Height",
"    <span class=\"nowrap\">",
"     (centimeters)/",
"    </span>",
"    Screat (enzymatic method)",
"   </p>",
"   <p>",
"    The formula is useful in the GFR range of 15 to",
"    <span class=\"nowrap\">",
"     75ml/min",
"    </span>",
"    per 1.73m2. Further validation studies are required to determine whether the use of this formula can be recommended for children without CKD and with higher levels of GFR.",
"   </p>",
"   <p>",
"    Children greater than two years of age can be classified into the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    stages of CKD based upon the level of kidney function as determined by their estimated GFR. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    classification is not appropriate for children less than two years of age, who normally have lower GFR values. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Definitions and classifications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Other laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory tests obtained in the evaluation of a child with CKD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrolytes &mdash; To detect electrolyte abnormalities, particularly hyperkalemia and metabolic acidosis (ie, low serum bicarbonate) (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Hyperkalemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Metabolic acidosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Complete blood count &mdash; To detect anemia (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Anemia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines define anemia as a hemoglobin (hematocrit) below the fifth percentile of normal when adjusted for age and sex (",
"      <a class=\"graphic graphic_table graphicRef57465 \" href=\"UTD.htm?5/34/5679\">",
"       table 5",
"      </a>",
"      ). At this point, the following evaluation is recommended, which is focused upon eliminating causes of anemia other than CKD and determining the iron status of the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Red blood cell indices &mdash; If the red blood cell indices are not consistent with a normocytic and normochromic anemia, which usually characterizes the anemia of CKD, then another cause of anemia should be considered.",
"     </li>",
"     <li>",
"      Reticulocyte count.",
"     </li>",
"     <li>",
"      Tests to determine iron status (serum iron, total iron binding capacity, percent transferrin saturation).",
"     </li>",
"     <li>",
"      Test for occult blood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This workup should be performed prior to the administration of any therapeutic interventions directed at correcting anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum calcium, phosphorus, 25-hydroxyvitamin D, and parathyroid hormone level to detect any abnormalities in bone mineral metabolism. (See",
"      <a class=\"local\" href=\"#H3526557\">",
"       'CKD-MBD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link\">",
"       \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fasting lipid profile that includes total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) to detect the presence of dyslipidemia. (See",
"      <a class=\"local\" href=\"#H174930617\">",
"       'Dyslipidemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinalysis &mdash; Urinalysis is a useful screening test for abnormalities of the kidney and urinary tract, and as an aid in identifying the underlying cause of CKD. The urinary dipstick makes it possible to test for protein, pH, concentration, glucose, hematuria, and pyuria. The different patterns of urinary findings associated with both acute and chronic kidney disease are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"       \"Urinalysis in the diagnosis of kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Proteinuria is an indicator of underlying glomerular disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tubular dysfunction, and is an important biomarker strongly associated with CKD. Ongoing urinary protein excretion may contribute to the progression of CKD. The severity of renal disease is generally associated with the amount and duration of proteinuria. Therefore, persistent high-grade proteinuria (2+ protein or greater) usually warrants a prompt evaluation for other signs of renal dysfunction. Lower levels of protein detected by urinary dipstick can usually be followed with repeated measurements to determine if there is resolution of proteinuria. The presence of persistent proteinuria by dipstick evaluation should be quantified by determination of the urine",
"      <span class=\"nowrap\">",
"       protein/creatinine",
"      </span>",
"      ratio. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link\">",
"       \"Evaluation of proteinuria in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidney biopsy &mdash; Tissue samples obtained via kidney biopsy are typically evaluated by light microscopy, immunofluorescence staining, and electron microscopy. Data from these studies may be useful in providing a diagnosis for the cause of CKD and guiding therapeutic choices. If a specific diagnosis is not possible, it often serves to exclude other disease entities in the differential diagnosis. The biopsy results also provide information about disease severity, including whether any abnormalities may be reversible and the degree of renal scarring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     FOLLOW-UP EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, CKD is progressive, and thus, children with CKD require ongoing monitoring of their kidney function, and screening for complications associated with CKD.",
"   </p>",
"   <p>",
"    Recommendations for the nutritional care of children with CKD are published in the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for Nutrition in Children with Chronic Kidney Disease: Update 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/46\">",
"     46",
"    </a>",
"    ]. These guidelines provide a schedule for health and nutritional surveillance in children with CKD (",
"    <a class=\"graphic graphic_table graphicRef52366 \" href=\"UTD.htm?13/11/13501\">",
"     table 6",
"    </a>",
"    ). More frequent assessments are recommended in younger children, and children with severe impairment regardless of age (ie, stages 4 and 5). In our practice, we monitor children with CKD based upon the schedule recommended by KDOQI guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If possible, children with CKD should be cared for by experienced clinicians (eg, pediatric nephrologists) in a multidisciplinary setting, in addition to their primary care provider. The following parameters should be closely monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?11/9/11418/abstract/8,47-55\">",
"     8,47-55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth including measurements of weight and height. For patients who are three years of age and younger, head circumference should also be measured.",
"     </li>",
"     <li>",
"      Blood pressure.",
"     </li>",
"     <li>",
"      Nutritional status.",
"     </li>",
"     <li>",
"      Laboratory tests, including serum creatinine, electrolytes, calcium and phosphorus, hemoglobin, fasting lipid profile, 25-hydroxyvitamin D, and parathyroid hormone level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we monitor children with CKD based upon the severity of their CKD and their age as illustrated in the linked table (",
"    <a class=\"graphic graphic_table graphicRef52366 \" href=\"UTD.htm?13/11/13501\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic kidney disease (CKD) refers to a state of irreversible kidney damage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reduction of kidney function, which can lead to progressive decreases in kidney function.",
"     </li>",
"     <li>",
"      The National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative",
"      <span class=\"nowrap\">",
"       (K/DOQI)",
"      </span>",
"      has defined CKD as a disorder lasting three or more months with either kidney damage defined by structural or functional abnormalities of the kidney, or an estimated glomerular filtration rate (GFR) of less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2. In addition, the",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      work group has developed a classification schema for patients with CKD who are older than two years of age based upon their level of kidney function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link\">",
"       \"Epidemiology, etiology, and course of chronic kidney disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical presentation of CKD is dependent upon the severity of renal impairment and the underlying disorder. Children with CKD can present in a variety of ways. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients in the early stages of CKD are often asymptomatic unless there are signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms that result directly from the underlying renal disease or systemic diseases with renal involvement.",
"     </li>",
"     <li>",
"      A patient's presentation with CKD may be due to an incidental finding, such as an elevation of their serum creatinine, abnormalities on urinalysis, or detection of renal disease by imaging studies, particularly prenatal ultrasonography.",
"     </li>",
"     <li>",
"      As CKD progresses, patients may present with poor growth.",
"     </li>",
"     <li>",
"      Patients with severe renal impairment or failure may present with signs and symptoms of uremia, such as weakness, fatigue, anorexia, or vomiting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of kidney function is associated with a number of complications due to impairment of the many functions performed by the kidney. These include disorders of fluid and electrolytes, mineral and bone disorders (CKD-MBD), anemia, hypertension, increased risk of premature cardiovascular disease and dyslipidemia, endocrine abnormalities, growth impairment, and decreased clearance of renally excreted substances from the body (uremia). As CKD progresses into the later stages of disease, the risk and severity of CKD associated complications increases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Complications of CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history include age at onset of symptoms, duration of symptoms, features of CKD (eg, hypertension or poor growth) or risk factors for CKD (eg, family history, or congenital anomaly of the kidney or urinary tract). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The examination of the child with suspected CKD should include measurement of blood pressure, growth parameters, assessment for the presence of pallor and volume status, examination of the extremities for bony deformities suggestive of CKD-MBD, and cardiac examination to detect any evidence of pericarditis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing is critical to determine the severity of renal impairment and to detect the presence of associated complications. Tests should include a serum creatinine, electrolytes, complete blood count, urinalysis and quantification of urinary protein by a urine protein to creatinine ratio. Other tests to consider include serum calcium, phosphorus, 25-hydroxyvitamin D, parathyroid hormone, and a fasting lipid profile. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Follow-up evaluation is required as CKD is often progressive. As a result, children with CKD require ongoing monitoring of their kidney function, with a goal of early identification and aggressive management of complications associated with CKD (",
"      <a class=\"graphic graphic_table graphicRef52366 \" href=\"UTD.htm?13/11/13501\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Follow-up evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/1\">",
"      Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007; 50:169.",
"     </a>",
"    </li>",
"    <li>",
"     NAPRTCS: 2008 Annual Report, Rockville, MD, EMMES, 2007 https://web.emmes.com/study/ped/announce.htm (Accessed on June 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/3\">",
"      Wong H, Mylrea K, Feber J, et al. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 2006; 70:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/4\">",
"      Furth SL, Abraham AG, Jerry-Fluker J, et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/5\">",
"      Seeherunvong W, Abitbol CL, Chandar J, et al. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 2009; 154:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/6\">",
"      van Husen M, Fischer AK, Lehnhardt A, et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010; 78:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/7\">",
"      Gerson A, Hwang W, Fiorenza J, et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004; 44:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/8\">",
"      K/DOQI Clinical practice guidelines for Bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/9\">",
"      Barrett IR, Papadimitriou DG. Skeletal disorders in children with renal failure. J Pediatr Orthop 1996; 16:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/10\">",
"      Salusky IB, Kuizon BG, J&uuml;ppner H. Special aspects of renal osteodystrophy in children. Semin Nephrol 2004; 24:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/11\">",
"      Fadrowski JJ, Pierce CB, Cole SR, et al. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 2008; 3:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/12\">",
"      Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999; 34:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/13\">",
"      Kausz AT, Obrador GT, Pereira BJ. Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 2000; 36:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/14\">",
"      Yorgin PD, Belson A, Al-Uzri AY, Alexander SR. The clinical efficacy of higher hematocrit levels in children with chronic renal insufficiency and those undergoing dialysis. Semin Nephrol 2001; 21:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/15\">",
"      Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 2012; 23:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/16\">",
"      Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/17\">",
"      Wilson AC, Schneider MF, Cox C, et al. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/18\">",
"      Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/19\">",
"      Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol 2008; 23:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/20\">",
"      Mitsnefes M, Flynn J, Cohn S, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010; 21:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/21\">",
"      Saland JM, Pierce CB, Mitsnefes MM, et al. Dyslipidemia in children with chronic kidney disease. Kidney Int 2010; 78:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/22\">",
"      T&ouml;nshoff B, Kiepe D, Ciarmatori S. Growth hormone/insulin-like growth factor system in children with chronic renal failure. Pediatr Nephrol 2005; 20:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/23\">",
"      van der Heijden BJ, van Dijk PC, Verrier-Jones K, et al. Renal replacement therapy in children: data from 12 registries in Europe. Pediatr Nephrol 2004; 19:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/24\">",
"      Greenbaum LA, Mu&ntilde;oz A, Schneider MF, et al. The association between abnormal birth history and growth in children with CKD. Clin J Am Soc Nephrol 2011; 6:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/25\">",
"      Lawry KW, Brouhard BH, Cunningham RJ. Cognitive functioning and school performance in children with renal failure. Pediatr Nephrol 1994; 8:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/26\">",
"      Warady BA, Belden B, Kohaut E. Neurodevelopmental outcome of children initiating peritoneal dialysis in early infancy. Pediatr Nephrol 1999; 13:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/27\">",
"      Qvist E, Pihko H, Fagerudd P, et al. Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood. Pediatr Transplant 2002; 6:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/28\">",
"      Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/29\">",
"      Roumelioti ME, Wentz A, Schneider MF, et al. Sleep and fatigue symptoms in children and adolescents with CKD: a cross-sectional analysis from the chronic kidney disease in children (CKiD) study. Am J Kidney Dis 2010; 55:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/30\">",
"      Sinha R, Davis ID, Matsuda-Abedini M. Sleep disturbances in children and adolescents with non-dialysis-dependent chronic kidney disease. Arch Pediatr Adolesc Med 2009; 163:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/31\">",
"      Davis ID, Greenbaum LA, Gipson D, et al. Prevalence of sleep disturbances in children and adolescents with chronic kidney disease. Pediatr Nephrol 2012; 27:451.",
"     </a>",
"    </li>",
"    <li>",
"     NAPRTCS: 2008 Annual Report, Rockville, MD, EMMES, 2007. Available at https://web.emmes.com/study/ped/announce.htm. (accessed on June 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/33\">",
"      Konu�� OL, Ozdemir A, Akkaya A, et al. Normal liver, spleen, and kidney dimensions in neonates, infants, and children: evaluation with sonography. AJR Am J Roentgenol 1998; 171:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/34\">",
"      Kadioglu A. Renal measurements, including length, parenchymal thickness, and medullary pyramid thickness, in healthy children: what are the normative ultrasound values? AJR Am J Roentgenol 2010; 194:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/35\">",
"      Rosenbaum DM, Korngold E, Teele RL. Sonographic assessment of renal length in normal children. AJR Am J Roentgenol 1984; 142:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/36\">",
"      Carrico CW, Zerin JM. Sonographic measurement of renal length in children: does the position of the patient matter? Pediatr Radiol 1996; 26:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/37\">",
"      Spira EM, Jacobi C, Frankenschmidt A, et al. Sonographic long-term study: paediatric growth charts for single kidneys. Arch Dis Child 2009; 94:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/38\">",
"      Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006; 21:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/39\">",
"      Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007; 72:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/40\">",
"      Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/41\">",
"      Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/42\">",
"      Counahan R, Chantler C, Ghazali S, et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976; 51:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/43\">",
"      Furth SL, Cole SR, Moxey-Mims M, et al. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 2006; 1:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/44\">",
"      Schwartz GJ, Mu&ntilde;oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/45\">",
"      Srivastava T, Alon US, Althahabi R, Garg U. Impact of standardization of creatinine methodology on the assessment of glomerular filtration rate in children. Pediatr Res 2009; 65:113.",
"     </a>",
"    </li>",
"    <li>",
"     K/DOQI clinical practice guidelines for Nutrition in Children with CKD: 2008 Update. Am J Kidney DIs 2009: 53:S1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/47\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/48\">",
"      Foster BJ, Leonard MB. Measuring nutritional status in children with chronic kidney disease. Am J Clin Nutr 2004; 80:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/49\">",
"      Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/50\">",
"      Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Greenbaum L, Schaefer FS. Pediatric Dialysis. In: Pediatric Dialysis, Warady, BA (Eds), Kluwer Academic Publishers, Dodrecht 2004. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/52\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/53\">",
"      Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41:I.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/54\">",
"      KDOQI, National Kidney Foundation. III. Clinical practice recommendations for anemia in chronic kidney disease in children. Am J Kidney Dis 2006; 47:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/9/11418/abstract/55\">",
"      Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6134 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11418=[""].join("\n");
var outline_f11_9_11418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPLICATIONS OF CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fluid and electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sodium and water balance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3526557\">",
"      CKD-MBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174930617\">",
"      - Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endocrine dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Growth impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Uremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Neurodevelopment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sleep and fatigue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EVALUATION AT PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Serum creatinine and GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Other laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      FOLLOW-UP EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6134|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6134|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/49/33566\" title=\"figure 1\">",
"      Normal kidney lengths age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6134|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/4/22603\" title=\"table 1\">",
"      Stages of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/61/20443\" title=\"table 2\">",
"      Normal GFR children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 3\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 4\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/34/5679\" title=\"table 5\">",
"      Normal hematologic values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13501\" title=\"table 6\">",
"      Nutritional assessment for children with CKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?23/40/24193?source=related_link\" title=\"calculator 3\">",
"      Calculator: Glomerular filtration rate estimate by Schwartz formula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=related_link\">",
"      Assessment of sleep disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=related_link\">",
"      Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/281?source=related_link\">",
"      Definition and screening for dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=related_link\">",
"      Epidemiology, etiology, and course of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17509?source=related_link\">",
"      Growth hormone metabolism in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=related_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6248?source=related_link\">",
"      Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=related_link\">",
"      Management of pediatric dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6533?source=related_link\">",
"      Pericarditis in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36484?source=related_link\">",
"      Reproductive and sexual dysfunction in uremic women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20951?source=related_link\">",
"      Sexual dysfunction in uremic men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2453?source=related_link\">",
"      Thyroid function in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_9_11419="Rome criteria for IBS";
var content_f11_9_11419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rome III diagnostic criteria* for irritable bowel syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recurrent abdominal pain or discomfort",
"        <sup>",
"         &bull;",
"        </sup>",
"        at least 3 days per month in the last 3 months associated with 2 or more of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (1) Improvement with defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (2) Onset associated with a change in frequency of stool",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (3) Onset associated with a change in form (appearance) of stool",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Discomfort means an uncomfortable sensation not described as pain. In pathophysiology research and clinical trials, a pain/discomfort frequency of at least 2 days a week during screening evaluation for subject eligibility.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11419=[""].join("\n");
var outline_f11_9_11419=null;
var title_f11_9_11420="Sxs distinguish CFS FM and TMD";
var content_f11_9_11420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms that distinguish between chronic fatigue syndrome, fibromyalgia, and temporomandibular joint disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms common to all three",
"conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle pain, aching, or discomfort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Problems falling or staying asleep, or sleeping too much",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wake up feeling tired, unrefreshed after a full night's",
"rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty concentrating or thinking, forgetfulness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain relieved by a bowel movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hard, loose, or watery stools",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms that",
"distinguish CFS and FM from TMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue greater than six months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue resulting in a 50 percent reduction of normal",
"activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained muscle weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migratory arthralgias without redness or swelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burning, shooting, or throbbing muscle pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms that",
"distinguish CFS from FM and TMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild fever (37.5&deg;C to 38.6&deg;C) or",
"chills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sore throat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms that",
"distinguish FM from CFS and TMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain made better by heat or massage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain made worse by sitting or standing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms that",
"distinguish TMD from CFS and FM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain in jaw muscles, temporomandibular joint, or inside",
"the ear",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CFS: chronic fatigue syndrome; FM: fibromyalgia; TMD: temporomandibular joint disorder.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Aaron, LA, Burke, MM, Buchwald, D, Arch Intern Med 2000; 160:221.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11420=[""].join("\n");
var outline_f11_9_11420=null;
var title_f11_9_11421="Neurotransmitters airway";
var content_f11_9_11421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurotransmitters found in nerve fibers innervating the airways: Origin, colocalization and effects on airway function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neurotransmitters*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Origin&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cotransmitters&Delta;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vasculature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glands",
"       </td>",
"       <td class=\"subtitle1\">",
"        Airway smooth muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetylcholine",
"       </td>",
"       <td>",
"        Parasympathetic",
"       </td>",
"       <td>",
"        Carbon monoxide",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        Secretion",
"       </td>",
"       <td>",
"        Contraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VIP&loz;",
"       </td>",
"       <td>",
"        Parasympathetic",
"       </td>",
"       <td>",
"        NO, PACAP",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        Secretion",
"       </td>",
"       <td>",
"        Relaxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitric Oxide (NO)&sect;",
"       </td>",
"       <td>",
"        Parasympathetic",
"       </td>",
"       <td>",
"        VIP, PACAP",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        Relaxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbon monoxide&yen;",
"       </td>",
"       <td>",
"        Parasympathetic",
"       </td>",
"       <td>",
"        Acetylcholine",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        Not assessed",
"       </td>",
"       <td>",
"        Relaxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norepinephrine",
"       </td>",
"       <td>",
"        Sympathetic",
"       </td>",
"       <td>",
"        Neuropeptide Y",
"       </td>",
"       <td>",
"        Vasoconstriction",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        Relaxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropeptide Y",
"       </td>",
"       <td>",
"        Sympathetic",
"       </td>",
"       <td>",
"        Norepinephrine",
"       </td>",
"       <td>",
"        Vasoconstriction",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CGRP&Dagger;",
"       </td>",
"       <td>",
"        Afferent",
"       </td>",
"       <td>",
"        SP, NKA",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance P (SP)**",
"       </td>",
"       <td>",
"        Afferent",
"       </td>",
"       <td>",
"        NKA, CGRP",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        Secretion",
"       </td>",
"       <td>",
"        Contraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurokinin A (NKA)",
"       </td>",
"       <td>",
"        Afferent",
"       </td>",
"       <td>",
"        SP, CGRP",
"       </td>",
"       <td>",
"        Vasodilatation",
"       </td>",
"       <td>",
"        Secretion",
"       </td>",
"       <td>",
"        Contraction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Other putative neurotransmitters have been localized to nerve fibers in the airways (eg, ATP, dynorphin, enkephalin, GABA, galanin, gastrin releasing peptide, glutamate, nociceptin, serotonin (5-HT), somatostatin). However, their function in the airways is poorly characterized.",
"     <br>",
"      &bull; Several neurotransmitters (e.g. neuropeptide Y, VIP) localized to nerve fibers innervating the airways are found in both sympathetic and parasympathetic nerves. Their primary origin is listed above.",
"      <br>",
"       &Delta; Multiple neurotransmitters are frequently localized to the same nerves. Such transmitters are known as cotransmitters. The most commonly colocalized neurotransmitters in the airways are listed above. Other examples of cotransmission (eg. galanin with VIP, dynorphin with substance P and neurokinin A) have been noted.",
"       <br>",
"        &loz; Vasoactive intestinal peptide and related peptides (peptide histidine isoleucine (PHI), peptide histidine methionine (PHM), pituitary adenylate cyclase activating peptide (PACAP), helodermin, helospectin)",
"        <br>",
"         &sect; Synthesized from arginine by nitric oxide synthase (NO synthase or NOS)",
"         <br>",
"          &yen; Synthesized from heme by heme oxygenase-2",
"          <br>",
"           &Dagger; Calcitonin gene-related peptide",
"           <br>",
"            ** Substance P has also been localized to a subset of airway parasympathetic ganglia neurons",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11421=[""].join("\n");
var outline_f11_9_11421=null;
var title_f11_9_11422="Cisplatin 60 plus etoposide for small cell lung cancer";
var content_f11_9_11422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cisplatin (60 mg/m",
"    <sup>",
"     2",
"    </sup>",
"    ) plus etoposide for extensive stage small cell lung cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"5\">",
"        Cycle length: Every 21 days for four cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td colspan=\"2\">",
"        Dilute in 250 mL normal saline (NS) and administer over 60 minutes. Do not administer with aluminum needles or sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Etoposide",
"        </strong>",
"       </td>",
"       <td>",
"        120 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV daily",
"       </td>",
"       <td colspan=\"2\">",
"        Dilute in 500 mL NS* or 5% dextrose in water (D5W) to final concentration &lt;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.",
"       </td>",
"       <td>",
"        Days 1, 2, and 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Routine prophylaxis not indicated. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with hematopoietic growth factors is not recommended. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . A lower starting dose of etoposide may be needed for patients with renal or liver impairment",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Basic metabolic panel (creatinine and electrolytes) and liver function tests prior to each cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Day 1 ANC should be &gt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets should be &gt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        for treatment during each cycle. Etoposide dose reductions should be based on the following table, taking into account the nadir ANC and platelet count along with day 1 ANC and platelet count for each cycle",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Etoposide dose",
"       </td>",
"       <td class=\"subtitle2\">",
"        Nadir ANC, cells/mm",
"       </td>",
"       <td class=\"subtitle2\">",
"        Nadir platelet count per mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Day 1 ANC",
"       </td>",
"       <td class=\"subtitle2\">",
"        Day 1 platelet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25 percent reduction",
"       </td>",
"       <td>",
"        750 to 999",
"       </td>",
"       <td>",
"        50,000 to 99,999",
"       </td>",
"       <td>",
"        Greater than 2000",
"       </td>",
"       <td>",
"        Greater than 100,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50 percent reduction",
"       </td>",
"       <td>",
"        Less than 750",
"       </td>",
"       <td>",
"        Less than 50,000",
"       </td>",
"       <td>",
"        Greater than 2000",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Hold",
"       </td>",
"       <td>",
"        Less than 750",
"       </td>",
"       <td>",
"        Less than 50,000",
"       </td>",
"       <td>",
"        1500 to 2000",
"       </td>",
"       <td>",
"        75,000 to 100,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Other severe non-hematologic toxicity:",
"        </strong>",
"        Etoposide and cisplatin should be withheld or doses decreased depending on clinical judgement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count; %: percent.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Schiller JH, et al. J Clin Oncol 2001; 19:2114.",
"      </li>",
"      <li>",
"       Toposar (etoposide) injection. FDA-approved package insert US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed December 8, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11422=[""].join("\n");
var outline_f11_9_11422=null;
var title_f11_9_11423="Abduction external rotation exercise for frozen shoulder";
var content_f11_9_11423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abduction and external rotation exercise for frozen shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise helps to improve both abduction and external rotation in patients with frozen shoulder. To perform the exercise, the patient lies down and, using the unaffected arm and a pillow as needed, gently abducts and externally rotates the shoulder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tore Prestgaard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_9_11423=[""].join("\n");
var outline_f11_9_11423=null;
